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ABSTRACT
Influenza A virus is a negative sense single stranded RNA virus responsible for
multiple devastating pandemics in the past. This virus is capable of entering multiple
eukaryotic hosts, sequestering, and using their cellular machinery for its own replicative
purposes. This plethora of molecular events is all orchestrated through a shockingly
limited repertoire of only 11 viral proteins. All of which are all strictly dependent on
cellular processes such as post-transcriptional regulation, protein translation, posttranslational modifications, etc. This study is focused on the characterization of the
interplay between Influenza A virus and the cellular SUMOylation system. The first part
of this dissertation deals with the effects imposed by Influenza A virus on the cellular
SUMOylation system. We demonstrate that SUMO-conjugation is upregulated in the
absence of any change in the levels of the enzymatic components of the SUMOcascade during viral infection with multiple influenza A strains. This event is
independent of toll-like receptor mediated- or IFN-β signaling cascades as the increase
in SUMOylation cannot be recapitulated by U.V. inactivated influenza viral particles nor
by the stimulation of cells with recombinant IFN-β. Furthermore, we also determined
that a transcriptionally active virus is required to trigger this increase in SUMOylation.
This finding is highly indicative that the factor responsible for this phenomenon is of viral
origin. Also, we show that both the early infected and non-infected cell populations
adjacent to infected cells experience an increase in nuclear accumulation of
SUMOylated proteins. In contrast, cells at late stages of infection experience a
decrease in overall SUMOylation. Finally, by using a mass spectrometry approach we
were able to identify multiple cellular as well as two viral proteins, namely M1 and NS1,
vii

as SUMO targets during infection. Moreover, we provided suggestive evidence where
SUMOylation seems to interfere with dimer and trimer formation of the NS1 viral protein.
The second part of this dissertation deals with the identification of the viral protein
Polymerase Basic 1 (PB1) as a bona fide SUMO target and the characterization of the
effects imposed by SUMO conjugation. Our results demonstrate that the overexpression
of the SUMO deconjugating enzyme SENP1 decreases the transcriptase activity of the
viral RNA-dependent RNA-polymerase during viral ribonucleoprotein reconstitution
assays. This decrease in transcriptase activity is not mediated by changing the cellular
localization of the viral polymerase. Also, by evaluating the accumulation of seven viral
proteins during infection we concluded that overexpressing SUMO1 leads to an
increase in viral protein production.
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I. GENERAL INTRODUCTION
1.1 Influenza virus and the Flu
Influenza is a negative sense segmented RNA virus that belongs to the
Orthomyxoviridae family containing all types of Influenza viruses and Thogoto virus [1,
2]. Influenza viruses are further divided into three different types: A, B, and C [1].
Influenza A and B are fairly similar, both bearing eight viral gene segments coding for
three integral membrane proteins that protrude from each of the infectious viral
particles: hemagglutinin (HA), neuraminidase (NA) and matrix 2 (M2) [3, 4]. In contrast,
the genome of Influenza C is limited to only seven gene segments, for which only two
code for integral membrane proteins commonly referred to as C matrix 2 (CM2) and
Hemagglutinin-Esterase-fusion (HEF) [3, 5]. These integral membrane proteins
determine the different tropisms of each individual Influenza virus by recognizing
extracellular receptors distributed throughout the cell’s glycocalyx. These glycoproteins
allow viral particles to adhere and internalize. Even though some of the viral proteins
among all three types are named similarly, they all have different lengths and their gene
segments vary in their non-coding and coding regions. This genetic and proteomic
variability reflects their divergent evolution.
All types of Influenza viruses have the ability to produce disease in human beings
[3]. However, Influenza A is considered the most pathogenic, being the only virus
capable of causing devastating pandemics. In comparison, Influenza B is associated
with relatively mild seasonal epidemics, and Influenza C is looked upon as a slight
sporadic respiratory disease [3]. For the purpose of this study, I will be focusing
exclusively on Influenza A virus.
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The most tragic pandemic to date produced by Influenza A is widely known as
the Spanish flu pandemic of 1918, which took the life of approximately 50 million people
worldwide [6]. Despite of the substantial progress in our antiviral arsenal achieved
during the last century, such as vaccine development and antiviral drugs, our ability to
control an influenza A pandemic is still limited. This was clearly demonstrated during the
recent 2009 H1N1 swine pandemic, which according to the World Health Organization
(WHO) started around April with a few cases in Mexico and California, and spread
throughout the world in less than three months.
The ability of Influenza A to cause pandemics is attributed to various evasive
maneuvers that the virus employs to surpass the host’s immune system. These allow
Influenza to infect both naïve and previously exposed hosts. One of these mechanisms,
known as antigenic shift, involves the exchange of gene segments coding for the viral
particle surface glycoproteins hemagglutinin and neuraminidase of the newly formed
virions. This exchange can only take place when two different viral strains replicate in
the same host [1, 7, 8]. Thus, preventing the recognition of the proteins encoded by the
newly incorporated viral gene segments by memory B and T cells in the host. As of
today, an extensive repertoire of 17 hemagglutinin and 10 neuraminidase isoforms have
been identified, all of which 16 HA and nine NA isoforms can be incorporated in the
newly synthesized infectious viral particle and create different combinations that will
give rise to new viral strains [9]. The final combination gives each Influenza A virus
subtype its particular reference name (e.g. H1N1). The second mechanism introduces
random changes in the sequence of each surface antigen in the viral envelope due to
the viral polymerase’s lack of proofreading activity and its high nucleotide substitution
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rate depicted in table 1 [10]. The point mutations introduced in the viral genome at the
time of genomic replication is another evasion mechanism employed by the virus known
as antigenic drift. As a consequence the amino acid sequence of the viral glycoproteins
is constantly changing over time [7]. Moreover, antigenic shift is not limited to only the
integral membrane proteins, but it can apply to all other viral gene segments [10-12].
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Table 1.- Nucleotide substitution rate introduced by the influenza viral polymerase.
Description of the nucleotide substitution rated determined by calculating the mean
number of non-synonymous and synonymous substitutions per mutated site caused by
an Avian Influenza viral polymerase in different natural hosts [10].
Influenza A Nucleotide Substitution Rate
(substitution/site/year)

Species

5.7 X 10-3

Human

1.8 - 8.4 X 10-3

Avian

5.1 - 5.4 X 10-4

Equine

1.30 X 10-3

Swine
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The primary immune responses triggered by Influenza A virus are complex and
beefier or worsen the condition of the infected individual. Influenza infection of an
immunologically naïve host results in viral replication in epithelial cells of the upper
respiratory tract. Viral replication causes morphological changes in the infected cells
such as shrinking and vacuolization followed by desquamation [3]. Depending on the
pathogenicity of the virus subtype, viral particles can disseminate to cells in the lower
respiratory tract causing bronchitis and alveolitis [3]. The infected epithelial cells will
mount an innate immunological response triggering the production of type I interferon,
chemokines and cytokines. The efficiency of this immune response will be critical for
preventing further dissemination of the virus. In contrast, some viral strains have the
ability to trigger a massive production of cytokines by plasmocytoid dendritic cells and
leukocytes recruited to the site of infection, which can lead to pulmonary lesions that
increase the damage produced by the virus and may result in fatal outcomes such as in
the case of people infected during the 1918 Spanish flu pandemic [3].
An additional immunological response that is of great relevance for decreasing
susceptibility to Influenza A infection is the presence of neutralizing antibodies in the
host’s sera [13]. The levels of neutralizing antibodies in the serum of newborn are the
same as those in their mother sera [13]. However, these neutralizing antibodies only
last for a couple of months after childbirth [13]. This increases the susceptibility of
infection in children between the age of 2 months and 5 years old [13]. The reason for
this being that children have never been exposed to Influenza A virus before [13]. On
the other hand, after 5 years of age preventive levels of neutralizing antibodies are more
commonly observed in children and continue rising until reaching their maximum at
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around the age of 20 [13]. This is the main reason why the percentage of the population
that is at greater risk includes those who are immunosupressed and young children [14].
Age is also an important factor in determining the effectiveness of the anti-influenza
responses in humans and susceptibility to Influenza A virus infection increase with age
due to the involution of the thymus that takes place after middle age. This process
decreases the levels of the thymic hormone, and even when the total numbers of Tlymphocytes remains unchanged, the levels of differentiated T-lymphocytes change
substantially. Additionally, further complications might also be involved in the
pathogenicity of Influenza A virus. These include secondary bacterial infections, which
are the main causing agents of pneumonia in Influenza infected patients, and
neurological complications such as seizures, encephalopathy, and acute necrotising
encephalitis in young children [3, 15, 16].
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1.2 Influenza A Viral Life Cycle
Influenza A virus is a negative sense single stranded RNA virus comprising eight
genomic segments encoding for 10-11 viral gene products depending on the viral strain
[1]. Mass spectrometry analyses have demonstrated that nine out of the eleven viral
proteins are incorporated into the infectious viral particle, namely Hemagglutinin (HA),
Matrix protein 1 (M1), Matrix protein 2 (M2), Neuraminidase (NA), Non-structural protein
2 (NS2) or Nuclear export protein (NEP), Nucleoprotein (NP), Polymerase basic 1
(PB1), Polymerase basic 2 (PB2), and Polymerase acidic (PA) [1, 17]. The other two
proteins, non-structural protein 1 (NS1) and Polymerase Basic 1 Frame 2 (PB1-F2), are
not incorporated in the infectious viral particle and therefore are considered to be nonstructural viral proteins [18].
Influenza infection beings after a viral particle attaches to sialyloligosaccharide
moieties covalently attached integral membrane proteins. These moieties are located in
the extracellular face of the plasma membrane of the host cell and allow internalization
of the viral particle via receptor-mediated endocytosis [19, 20]. The sialic acid modifying
the integral membrane protein can either have a N-Acetylneuramic acid (α2,3) Dgalactose linkage, such as in the case of the epithelial cells lining intestinal tract of
aquatic birds, or N-Acetylneuramic acid (α2,6) D-galactose linkage, abundant in the
epithelial cells of the human respiratory tract [21-23]. Each viral strain has a different
affinity for each type of linkage and thus restrict Influenza A virus from spreading across
species [17, 22].
Upon attachment, the viral particle is internalized by endocytosis into an
endocytic vesicle, which subsequently fuses with numerous lysosomes, a process
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required for effective viral infection [20]. The low pH of the lysosome triggers a
conformational change in the glycoprotein HA, accommodating its two subunits properly
for membrane fusion. The HA1 subunit has the sialic acid binding domain, while the HA2
subunit contains the fusion peptide , which is rich in acidic residues. The acidic pH
created by the fusion of the lysozome helps in the protonation of the fusion peptide and
allows its internalization in the endosomal membrane by increasing its hydrophobicity
[20]. This event brings both the viral and the endocytic vesicle membranes into close
proximity allowing membrane fusion [20]. The HA1 and HA2 subunits are generated by
the proteolytic cleavage of the viral glycoprotein HA during its cellular translocation from
the smooth endoplasmic reticulum to the plasma membrane prior to budding [24].
In addition to its role in triggering membrane fusion, the low pH of the lysosome
also triggers the acidification of the viral particle core, thanks to the tetrameric
transmembrane ion channel made by the M2 viral protein, which allows the passage of
H+ ions through the viral envelope into the viral particle. The acidification of the viral
particle core also weakens of the intermolecular interactions between the viral
ribonucleoparticles (vRNPs) and the M1 capsid protein, thus allowing the vRNPs to be
released into the host cell cytoplasm upon membrane fusion, in close proximity to the
nucleus [25, 26]. Then, each viral ribonucleoparticle translocates into the nucleus
through the nuclear pore complex with the help of nuclear transport factors (importins)
[27-29]. The internalization of the vRNPs is mediated via the direct interaction between
NP and either importin α3 or importin α5 [25, 26].
Like every negative sense RNA virus, Influenza must attach to each infectious
viral particle a functional RNA-dependent RNA-polymerase (RdRp) to transcribe and
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replicate its genome [1]. Influenza’s RdRp is a heterotrimeric complex composed of
PB1, PB2, and PA [17]. The viral polymerase is packaged inside the viral particle in
close interaction with each of the eight viral gene segments forming ribonucleoprotein
complexes [17, 30, 31]. Three viral proteins, NP, PB2, and PB1, are the main factors
mediating the interaction between the viral polymerase and each of the vRNA segments
[32]. Additionally, PB1 recognizes and interacts with the viral promoters located at the 3’
and 5’ end of each viral gene segment [33]. After being transcribed and translated, NP
is translocated into the nucleus via nuclear pore complexes and wraps around all of the
eight vRNA gene segments, protecting them from nuclease degradation and acting as a
docking site for the viral polymerase [32, 34]. Additionally, NP’s ability to oligomerize
and form vRNP-like structures, even in the absence of vRNA, helps keep the threedimensional conformation of the vRNPs and further facilitates its interactions with other
viral proteins [35]. The interaction between PB1 and NP brings PB1 into close proximity
with the viral RNA 3’ and 5’ ends.
Viral mRNA transcription initiates in a primer-dependent manner using the vRNA
molecules from the incoming virion as template [36]. Viral gene transcription begins as
early as 1hr post-infection and is coupled with the translation of the early gene products,
which include the three subunits of the viral polymerase, NP, and NS1 [37]. NS1 is a
multifunctional viral protein that regulates a plethora of viral-host interactions, and viral
polymerase functions [38]. Among others, NS1 is involved in the regulation of vRNA
synthesis, the down-regulation of cellular innate immune responses (mainly those
associated in type I IFN production and the recognition of double stranded RNA), and
the up-regulation of viral mRNA translation in IFN-competent cells [39-42].
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Viral gene transcription driven by the viral RdRp continues throughout infection
[37]. However, even though early protein gene transcripts appear soon after
internalization of the viral particle, both early and late viral mRNA transcripts seem to
reach their maximum level at four and a half hours after infection [37]. Soon thereafter,
the levels of viral mRNA start decaying, but the translation of viral proteins goes on
driven by the already existent mRNA population [37]. Late viral genes encode for
proteins involved in the nuclear export and packaging of the vRNPs or transmembrane
proteins essential for budding [37].
Influenza virus takes advantage of several cellular factors, since the endogenous
cellular ribosomal machinery translates all viral mRNA [43]. In order for the cellular
ribosomes to recognize the viral mRNA molecules, the viral polymerase interacts with
the 7-methylguanosine 5’-cap from cellular mRNAs and enzymatically cleaves it and
attaches it to viral mRNA molecules [43]. This enzymatic reaction, known as capsnatching, is catalyzed by the PA subunit and is dependent upon binding of the 3’-end
of the vRNA molecules and the viral polymerase complex [44, 45]. The PA protein
contains the endonucleolytic domain, which is part of the super family of type II
restriction enzymes bearing a PD-(D/E)-XK motif [44, 46]. The host pre-mRNAs are
cleaved 9-17 nucleotides downstream of the 5’-cap structure only at guanine or adenine
residues. More importantly, PB2 is the subunit that recognizes and interacts with the 5’cap structure of cellular mRNAs. Its recognition is dependent upon a conformational
change triggered by the interaction between the viral polymerase complex and the 5’end of the vRNA [45, 47]. Finally, just like any other cellular mRNA, viral mRNAs are
polyadenylated, but unlike host mRNA transcripts, the viral mRNAs are polyadenylated
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thanks to the presence of the uridine-rich sequence 17 to 22 nucleotides away from the
5’ end of the vRNA [48], in a process independent from the action of the cellular
polyadenylating machinery. Polyadenylation of the viral mRNAs happens because the
RdRp remains bound to the 5’-end of the template throughout the course of
transcription [49]. Therefore, the restrains inflicted by the intermolecular interactions
shared between the 5’-end of the vRNA and the viral polymerase will produce
polymerase stuttering and will allow for polyadenylation to occur [49].
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Figure 1. Viral mRNA transcription.
The structure of the viral ribonucleoprotein complex is shown under figure 1.1, with PB1
(red), PB2 (black), PA (purple), and NP (light gray). Figure 1.2 shows the interaction
between the viral protein PB2 and the 5’-cap of the cellular mRNA (yellow line). Also,
the cap-snatching event is depicted by the two adjacent red lines under the viral protein
PA. Figure 1.3 shows how the viral polymerase utilized the 5’-cap from cellular mRNAs
to prime the transcription of viral mRNAs (blue line). Figure 1.4 demonstrates how the
viral polymerase reaches the uridine-rich region near the 5’-end of the vRNA, stutters,
and introduces the polyadenylation tail in the viral mRNA.
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At a given time during influenza infection the viral polymerase switches from
transcribing viral mRNAs into transcribing complementary RNAs (cRNAs) by a
mechanism that remains to be conclusively elucidated [50]. One of the most recent and
accepted mechanisms involves the production of Influenza A virus-derived small viral
RNAs that constitute the 5’-end of the vRNA gene segments [51]. These svRNAs are
produced along the course of infection and their accumulation and physical interaction
with the polymerase machinery triggers the switch from transcription to replication [51].
The viral cRNA molecules have the exact sequence complementary to the viral genome
and are transcribed in a primer-independent manner to be used as templates for
Influenza’s genomic replication [50]. Viral RNA levels synthesized during replication are
maximized at five and a half hours post-infection [37]. Accumulation of vRNA in the host
cell is indicative of a late stage during influenza’s replication cycle and is coupled with
the accumulation of the transmembrane proteins HA, NA and M2 in lipid rafts at the
apical cell surface [24, 52-54]. The cellular localization of both HA and NA proteins is
directed by apical sorting signals present at their transmembrane domains and is
independent of any additional viral proteins [52, 53]. An extra viral polypeptide crucial
for initiation of viral particle budding is M1, which accumulates at the site of budding by
protein interactions that are still disputable as of today [54]. Several studies have
indicated that M1 localization at adjacent regions in the plasma membrane is
independent of HA and NA expression but their direct interactions have not been yet
ruled out [55]. Furthermore, an additional activity mediated by M1 is the export of the
vRNPs from the nucleus. The nuclear export of the newly synthesized vRNPs is
mediated by a bundle of interacting partners involving M1, NEP, and the cellular export
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factor CRM1. The C-terminus of NEP masks the nuclear localization signal (NLS) at the
N-terminus of M1, while the N-terminus of NEP containing a basic sequence interacts
with CRM1 in a nuclear export signal (NES)-independent manner [56, 57]. Additionally,
studies indicate that the C-terminus of M1 directly interacts with vRNPs in vitro [46].
Taking all of these protein interactions into consideration it has been postulated that the
nuclear export of vRNPs involves the formation of “daisy-chain” complexes composed
of CRM1 and RanGTP, NES-NEP, M1, and vRNPs. Once the vRNPs are exported out
of the nucleus, they migrate towards the site of budding at the plasma membrane [56].
The morphology of the budded infectious viral particle is affected by the lipid
composition making them spherical or rod shaped [58, 59]. Lastly, the infectious viral
particle is released from the cell by the enzymatic cleavage of sialic acid receptors
present at plasma membrane mediated by sialidase enzymatic activity of the
neuraminidase viral glycoprotein [60].
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1.3 SUMOylation
SUMOylation is a reversible post-translational modification that involves the
dynamic conjugation and de-conjugation of SUMO (Small Ubiquitin-like MOdifier) to
different cellular protein targets. SUMO is a polypeptide constitutively expressed and
functional in all eukaryotic organisms, including Fungi, Plantae, and Animalia [61-64].
The SUMO peptide has four different homologs in mammals, SUMO1, SUMO2,
SUMO3 and SUMO4 [65, 66]. SUMO2 and SUMO3 share 97% identity and are
commonly referred to as SUMO2/3. In contrast, SUMO4 shares 87% amino acid identity
with SUMO2, but has an amino acid substitution at residue number 90 from glycine to
proline, which introduces a kink in its three dimensional structure and renders it
resistant to protease cleavage and maturation for conjugation in vivo [67]. SUMO1 is
substantially different from all other SUMO proteins sharing only 50% identity with
SUMO2/3.
In relation with Ubiquitin, SUMO1 is the most closely related SUMO homolog,
sharing 18% identity and 40% similarity to Ubiquitin. The SUMO conjugation pathway
resembles that of Ubiquitin, since it also involves E1, E2, and E3 enzymes [62, 64].
SUMO conjugation can alter the modified target, including altering its enzymatic activity,
changing its cellular localization, and acting as docking sites for additional regulatory or
interacting molecules. In contrast, poly-ubiquitination is frequently linked with protein
degradation.
SUMO is initially synthesized in the cell as a peptide precursor that needs to be
proteolytically cleaved at its C-terminus by specific SUMO proteases known as Sentrin
Proteases (SENPs) [68, 69]. This proteolytic cleavage exposes a di-glycine motif
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required for the recognition by the SAE1/SAE2 (SUMO-activating enzymes 1 and 2)
heterodimer, also known as the E1 SUMO enzyme in the SUMOylation pathway [7073]. The SUMO activating enzyme adenylates the glycine residue at the C-terminus of
SUMO in an ATP-dependent reaction, and through the release of AMP forms a thioester
linkage with the SAE2 subunit containing the active cysteine residue at position 173
[73].

After being activated, the SUMO peptide is transferred to the E2 SUMO-

conjugating enzyme Ubc9, also forming a thioester linkage with a cysteine residue at
position 93 [70, 74]. In contrast to Ubiquitin, E3 ligases are not required for
SUMOylation; however, they enhance conjugation and provide target specificity [72].
During SUMO conjugation, an isopeptide bond is formed between the carboxyl group of
the C-terminal glycine residue in SUMO and the epsilon amino group of a lysine residue
in the target protein [70]. Another disparity between SUMO and ubiquitin is that a
consensus site that favors SUMOylation has been identified, whereas there is no
ubiquitination consensus motif. The SUMOylation consensus site follows the sequence
“ψKxE,” where ψ is a bulky hydrophobic amino acid, and x is any amino acid followed
by a glutamic acid. However, this consensus motif is present only in about half of all the
SUMOylation sites characterized to date. Even though, SUMOylation is very similar to
ubiquitination, it exerts a very different set of effects in its target proteins. Furthermore,
different SUMOs also exert different effects, a property that could be attributed to the
extra amino acids present at the N-terminus each of the SUMO proteins [68].
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Figure 2. The SUMOylation pathway.
This figure shows how SUMO is synthesized as an immature precursor that needs to be
proteolytically processed by SUMO proteases before its conjugation. After the removal
of the extra amino acids located after the di-glycine motif at the c-terminus, the SUMO
protein then interacts with the E1 activating enzyme, and in an ATP-dependent reaction
it becomes activated. After activation the SUMO protein then is transferred to the E2
conjugating enzyme, which recognizes and attaches the SUMO moiety to its target
proteins. Once again the SUMO proteases can cleave the SUMO protein from its target,
leaving the SUMOylated protein intact and the SUMO moiety ready to become
conjugated again.
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1.4 Viruses and SUMOylation
Even though SUMOylation is a post-translational modification system that
typically interacts and regulates endogenous cellular protein functions, several viruses
are known to utilize some component(s) of this cellular system in order to create a more
favorable environment for their replication cycle. A common interaction between cellular
SUMOylation and viral infection is mediated by the attachment of SUMO to viral
proteins. Some examples of viral proteins that are currently known to be SUMOylated
are the E1 and L2 proteins from Human and Bovine Papillomaviruses (HPV and BPV),
the BZLF1 protein from Epstein-Barr virus (EBV), the N protein from Severe Acute
Respiratory Syndrome-Coronavirus (SARS-CoV), the two immediate early (IE) proteins
IE1 and IE2 of Human Cytomegalovirus (HCMV), and the IN protein of Human
Immunodeficiency virus type-1 (HIV-1), among many others [75-82]. In comparison to
SUMO-modified cellular proteins, the effect imposed by the SUMO-conjugation event on
the individual viral peptides varies substantially, and might be of relevance for their
functionality during infection. Subsequently, just like for cellular SUMO substrates, some
of the effects mediated by SUMOylation upon the previously mentioned viral peptides
include

altering

protein

stability,

protein

oligomerization,

cellular

localization,

intranuclear targeting, and transcriptional regulation.
Nevertheless, viral interactions with the cellular SUMOylation system are not only
limited to SUMO-conjugation of their viral peptides. For instance, several viral proteins
also interact non-covalently with SUMO, Ubc9, SAE1, or SAE2. Some viruses
exemplifying these types of interactions with the cellular SUMOylation system include
Avian Adenoviruses, Encephalomyocarditis virus (EMCV), and type-2 Dengue virus
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(DV). [83-85]. Among them all, the mechanism of inhibition of the cellular SUMOylation
system by the Avian Adenovirus protein Gam-1 is perhaps the most characterized
example to date [86]. This viral protein acts as a recruiter of a protein complex
composed of EloB (Elongin B), EloC (Elongin C), Roc1 (RING protein), Cul2 (Cullin 2),
and Cul5 (Cullin 5), which altogether form an E3 ubiquitin ligase. Consequently, this
protein

complex

triggers

the

poly-ubiquitination

and

proteasomal-dependent

degradation of SAE1 [86, 87]. Furthermore, due to the mutualistic stabilization achieved
by the two protein components of the E1 heterodimmer, the degradation of SAE1
triggers the subsequent degradation of SAE2 [87]. This prevents the activation of
SUMO, and therefore, reduces cellular SUMOylation levels. One of the main
consequences of the SAE1-degradatory activity exerted by Gam1 and its subsequent
downregulation of cellular SUMOylation is the disruption of promyelocytic leukemia
nuclear bodies (PML-NBs), which are mainly composed SUMOylated proteins. Since
the PML-NBs are involved in the cellular antiviral state as indicated by their enhanced
size during an interferon (IFN) response, their disruption creates an environment where
adenoviral replication is favored. In support of the relevance of this phenomenon, it has
been observed that adenoviruses lacking Gam1 cannot replicate [88]. Similarly, EMCV,
and type-2 DV will interact with Ubc-9 in order to promote the SUMOylation dependent
degradation of PML-NBs or to trigger their nuclear dispersion [83, 84]. However, the
purpose of disregulating the SUMO system might be more complicated, since
SUMOylation is also involved in additional elements of the cellular antiviral response,
like IRF-3 and IRF-7, which are transcription factors critical for activation of the IFN
genes [89].
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Despite the fact that viral replication tends to be favored in cellular environments
with low SUMOylation levels, during Influenza viral infection there is an upregulation in
cellular SUMOylation that takes place eight hours post-infection [85]. This upregulation
is characterized by an increase in the pool of the SUMOylated cellular proteins of high
molecular weight, and is also accompanied by the appearance of three new
SUMOylated bands of approximately 37, 50, and 75 kDa [85]. Furthermore, this global
increase in cellular SUMOylation requires a transcriptionally active virus, but does not
require the induction of an antiviral state by exogenous interferon [85]. More importantly,
this increase in cellular SUMOylation occurs without altering the endogenous levels of
Ubc9, SAE1/SAE2, or SENP1 [85].
The effect imposed by influenza on the cellular SUMOylation system during
infection is coupled with the SUMO-conjugation of seven influenza viral proteins, five of
which have already been reported in the literature (NP, NS1, NS2, PB1, and M1) and
two of which were only recently identified in a mass spectrometric analysis, PB2 and
PB1-F2 (unpublished data) [85, 90, 91]. Of the five viral proteins reported to be
SUMOylated, only the role of SUMOylation for M1 has been solidly characterized. For
this viral protein, SUMO-conjugation appears important for M1-mediated viral
morphogenesis, and for establishing the protein-protein interactions required for viral
ribonucleoprotein assembly [91]. However, the roles of the remaining SUMOconjugation events affecting other Influenza proteins still remain partially (for NS1) or
completely uncharacterized (for all other SUMOylated influenza proteins).
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II. HYPOTHESIS
Several published studies using genome-wide expression profiling, and genomewide RNA interfering, have identified components of the SUMOylation pathway such as
SUMO-1, SUMO-2, SUMO-4, SAE1, and Ubc9, as essential components required for
early-stages during influenza viral infection [92-94]. In addition, we have substantial
data showing that overexpression of SUMO either in its conjugatable or nonconjugatable form induces an increase in the levels of viral antigens produced during
infection (unpublished data). Thus, we hypothesize that SUMOylation is an essential
cellular post-translational modification for influenza virus, playing a beneficial role for its
replication and propagation. Therefore, the increase in cellular SUMOylation observed
during infection is directed against proteins that play an essential role during influenza
virus life cycle, and that could be targeted for the future development of broad-spectrum
therapeutic agents against this pathogen. Moreover, SUMOylation can act as an
additional regulatory mechanism through its dynamic conjugation and de-conjugation to
viral antigens, having an effect in their function, cellular localization or acting as a
docking site for additional proteins to interact with them.
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III. SPECIFIC AIMS
To address the hypothetical scenario presented above, we proposed the following
specific aims:
1. Characterize the effects inflicted by Influenza A virus infection on the cellular
SUMOylation system and vice versa.
2. Test whether the Polymerase Basic 1 viral protein (PB1) constitutes a bona fide
SUMO target and determine whether the fluctuations in SUMO-conjugation
observed during influenza A infection affect its transcriptase or/and replicase
activities.
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CHAPTER 1: THE CHARACTERIZATION OF THE EFFECTS INFLICTED BY
INFLUENZA A VIRUS INFECTION ON THE CELLULAR SUMOYLATION SYSTEM
AND VICE VERSA
1.1

Introduction
Influenza A is a highly pathogenic virus responsible for the death of 36,000

people and >100,000 hospitalizations in the United States alone on a yearly basis. The
high transmissibility of the virus due to the aerosolized viral particles formed after
sneezing makes preventive measures hard to implement among an infected population.
As of today there are only two types of antiviral drugs regularly administered to
influenza infected individuals: Neuraminidase inhibitors and ion channel inhibitors.
Neuraminidase inhibitors (e.g. Oseltamivir and Zanamivir) resemble a sialic acid moiety,
which allows recognition and permanent binding to the integral membrane viral protein
Neuraminidase. This permanent interaction blocks the sialidase activity of the viral
protein neuraminidase required during viral budding by creating steric hindrance. Ion
channel inhibitors (e.g. Amantidine and Rimantidine) on the other hand, bind and block
the viral ion channel and therefore, prevent the acidification of the viral particle at early
stages during infection. However, both antiviral drugs have to be administered soon
after infection in order to be effective, and unfortunately the majority of the circulating
strains have already developed resistance to Amantidine, while some other strains have
been also shown to be resistant to Oseltamivir. An additional preventive measure
commonly used against Influenza A virus infection is annual vaccination. Nevertheless,
vaccine development is a very time consuming procedure that is error prone because
the selection of the strains to be included in the vaccine each year is based solely on an
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educated guess of the viral strain most likely to become the predominant circulating
strain during the upcoming influenza season. Furthermore, the high mutation rate
exhibited by the proofreading-deficient viral polymerase renders annual vaccinations
largely ineffective against subsequent annual epidemics.
Given the clear need for new and more effective antiviral therapies it becomes
essential to further characterize the cellular mechanisms that are essential for viral
replication. The high dependency of influenza A virus on a functional SUMO system for
efficient viral replication, and the fact that several viral proteins are SUMO-conjugated
indicate that SUMOylation could be targeted to develop new antiviral therapies.
However, the interaction between SUMOylation and Influenza has not been completely
characterized, and it is therefore referred to as having an unknown functionality in the
literature. As stated above, the characterization of this interaction between cellular
SUMOylation and influenza can lead to the identification of essential cellular
SUMOylated proteins that can be used as targets for the development of future broadspectrum therapeutic treatments to neutralize viral infection and propagation.
Nonetheless, the interaction between this cellular post-translational modification
and Influenza viral infection is bidirectional. This means that in order to fully characterize
the interaction we have to address how influenza A virus affects the cellular
SUMOylation system, and how SUMOylation affects influenza A virus during infection.
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1.2 Material and methods
Viruses and mammalian cell cultures
HEK293A cells (invitrogen Corp., Carlsbad, CA), A549 Cells (ATCC, Manassas, VA),
and MDCK cells (ATCC) were maintained in 1x Dubelcco’s modified essential medium
(DMEM) supplemented with high glucose, L-glutamine, sodium pyruvate, and 10% fetal
bovine serum. The cells were maintained in a 37°C incubator at 5% CO2, and split every
48 h at a 1:5 ratio. Influenza A/PR/8/34 (H1N1) and A/Vic/77 (H3N2) were a gift from Dr.
John M. Quarles (Dept. of Microbial and Molecular Pathogenesis, College of Medicine,
Texas A&M Health Science Center). All viruses were propagated in MDCK cells at a
multiplicity of infection (MOI) of 0.001 using 1xDMEM supplemented with 0.2% bovine
serum albumin (BSA) and 2µg/mL of L-(Tosylamido-2-phenyl) ethyl chloromethyl ketone
(TPCK)-treated trypsin (Worthington Biochemical Corp., Lakewood, NJ).

Immunofluorescent Assays
For immunofluorescence analysis A549 cells were plated in a 96-well plate (plack flat
bottom) and allowed to reach confluency. Cells were either mock infected or infected
with Influenza H1N1 A/WSN/1933 at an MOI of 10. The cells were fixed with 1x PBS + 4%
Paraformaldehyde at different times post-infection (0, 3, 6, 9, 12, 16, 20, and 24 hrs).
Then, the cells were permeabilized by incubating with methanol for 10 mins at 4°C.
After permeabilization, the cells were incubated with anti-M1 MAb clone GA2B
(Meridian Life Science, Inc.) at a dilution of 1:100 and anti-SUMO1 Y299 (Epitomics Inc.
Burlingame, CA) at a dilution 1:250 in 1xPBS supplemented with 1% goat serum and
incubated overnight at 4°C. Excess antibody was removed with three washes of 5
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minutes each with 1x PBS. Fluorescently labeled secondary antibodies, namely highly
cross-absorbed Alexa Fluor® 488 goat anti-mouse IgG and highly cross-absorbed
Alexa Fluor® 594 goat anti-rabbit IgG (both from Molecular Probes®, Life Technologies
Corp., Carlsbad, CA) were added to the cells in 1x PBS supplemented with 1% goat
serum at a dilution of 1:500 and incubated for 1hr at room temperature (RT°). Once
again, the cells were washed three times with 1x PBS, then incubated with 4',6diamidino-2-phenylindole (DAPI) at a concentration of 5 µg/mL for 5 minutes and
washed three additional times with 1x PBS. The images were captured by using an
LSM 700 confocal microscope (Zeiss. New York, NY) with a 63X objective and three
lasers at 405 (DAPI) nm, 488 (Alexa) nm, and 555 (Alexa) nm. The microscope was
assisted by the ZEN 2009 software (Zeiss. New York, NY), designed for acquisition and
processing of confocal images. Since the microscope system is equipped with
monochromatic camera (black and white), we applied computerized pseudocolor to
achieve the final colored images presented using the ZEN 2009 software (Zeiss. New
York, NY). Additionally, the ZEN 2009 software to process the confocal images
captured and delineate the area representing the nucleus as indicated by the DAPI
stain. This was done for a total of 50 cells per time point. We decided to choose the
nucleus for the quantification of the signal for SUMO1, due to the extensive
accumulation of SUMO1 in this cellular compartment.

Recombinant Adenoviruses
Recombinant adenoviruses were developed by using the ViraPowerTM Adenoviral
Gateway® Expression System. Bicistronic constructs present in a pENTR1A donor
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plasmid coding for a His-S-tagged form of SUMO1 and an HA-tagged form of Ubc9
were cloned into the pAd/CMV/V5-DEST destination plasmid. Cloning required a
recombination reaction driven by the Gateway® LR clonase II enzyme. The insertion
was confirmed by restriction analysis. The pAd/CMV/V5-DEST plasmid allowed for
recombinant adenoviruses to propagate after Pac I digestion and transfection into
HEK293A cells. For viral propagation, the methodology mentioned in Luo et al. 2007
was followed [95]. All the recombinant adenoviruses mentioned in this study were
created in the same way but they express either the wild type or mutated forms of HisS-SUMO1 and HA-Ubc9. Titers for the recombinant adenoviruses were determined by a
spot assay using an anti-hexon mouse MAb (Santa 284 Cruz Biotechnology, Inc.) and
the ImmunoPure® metal enhanced DAB substrate kit (Pierce Protein Research
Products, Thermo Fisher 286 Scientific Inc. Rockford, IL) as previously reported [96].

Tandem affinity purification for mass spectrometry analysis
A549 (ATCC, Manassas, VA) cells were seeded in six T-175cm2 flasks and
allowed to reach ~95% confluency. For the purpose of this experiment, three
recombinant adenoviruses were developed by using the pAd/CMV/V5-DESTTM
Gateway Vector kit and the methodology thoroughly described in Pal et. al. 2009.
Each recombinant adenovirus contains a bicistronic plasmid for the overexpression of
either a His and S-peptide tagged form of SUMO1 and Ubc9, a His and S-peptide
tagged form of SUMO1 lacking the C-terminal di-glycine motif and Ubc9, or a His and Speptide tagged form of SUMO1 with glutamine to proline amino acid substitution at
position 94 and Ubc9. This latter mutation makes SUMO to be non-deconjugatable
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upon its attachment to a target protein. Cells were transduced with the appropiate
adenoviruse and placed in a 37°C incubator with 5% CO2 for 48h to allow
overexpression of the adenovirus-encoded transgenes. Selected A549 cell cultures
were then infected with Influenza H1N1 A/WSN/1933 at a multiplicity of infection (MOI)
of 10 by resuspending active virus in 1xDMEM supplemented with high glucose, Lglutamine, sodium pyruvate, and 0.2% BSA. Selected samples were mock infected by
replacing the supernatant with 1xDMEM supplemented with 0.2% BSA. All samples
were maintained in a 37°C incubator with 5% CO2 for 30h prior to collection. Total cell
extracts were collected at 4°C in 5mL of denaturing buffer (8M urea, 100mM NaH2PO4,
10mM Tris, 0.2% Triton X-100, 20mM N-ethylmaleimide, pH 8.0), and the resulting total
cell extract was sonicated using a 1/8-inch probe for periods of 1 minute at an amplitude
of ≤ 40 amps with 5 seconds-long pulses at 2 seconds intervals. A 100µL aliquot of the
resulting extract was mixed with an equal volume of 4x sample buffer for direct
immunoblot analysis. The remaining 4.9 mL of each sample was incubated individually
with 800 µL of a 50% slurry of Ni-NTA beads (Quiagen, Invitrogen) for 2 h at 4°C in an
orbital rocker. The total cell extract-beads mixture was poured over an empty
chromatography column. The flow-through was discarded and the packed beads were
subsequently washed with 20 mL of each of the following buffers (ice cold): buffer #1 (8
M urea, 100 mM NaH2PO4, 10 mM Tris, 10 mM imidazole, pH 8.0), buffer #2 (1 M urea,
100 mM NaH2PO4, 10 mM Tris, 10 mM imidazole, pH 8.0), and buffer #3 (100 mM
NaH2PO4, 10 mM Tris, 10 mM imidazole, pH 8.0). The bound proteins were eluded by
the addition of 3.5 mL of 1xTBS supplemented with 500 mM imidazole. The eluted
samples were dialyzed against 6 L of 1x TBS to dilute out the imidazole. Again, a 100µL
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of the resulting extract was mixed with an equal volume of 4x sample buffer for direct
immunoblot analysis. The remaining 3.4 mL of each sample were incubated individually
with 400 µL of a 50% slurry of S-protein agarose beads (Novagen, EMD Biosciences
Inc.) for 18 h at 4° C in a orbital rocker. Once more, the total cell extract-beads mixture
was poured over an empty chromatography column, and the packed beads were
washed with 100mL of ice cold 1xTBS. The packed beads together with the bound
proteins were collected by resuspending them in 1mL of 1xTBS and transferring them
into a 1.5mL centrifuge tube. Once again, 50µL of the resulting extract was mixed with
an equal volume of 4x sample buffer for direct immunoblot analysis. The rest of the
collected extract will be used for mass spectrometric analysis.
To further clarify the identity and purpose of each sample, please refer to table
1.1.
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Table 1.1- Summary of the treatments applied to each sample and their experimental
purpose during the mass spectrometry analysis.
Sample
#

Transduced

Influenza
infected

Used as

1

-

+

(-) Ctrl

2

AdV-DualS1

-

Exp

3

AdV-DualS1

+

Exp

4

AdVDualS1ΔGG

+

(-) Ctrl

5

AdVDualS1Q94P

-

Exp

6

AdVDualS1Q94P

+

Exp
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Purpose of sample
Lacks tagged form of SUMO; Used
to observe the background of
cellular and viral proteins capable of
binding to the beads despite not
being tagged with the tandem
affinity purification system used.
Not-infected sample; Used to
observe cellular proteins that are
targeted for SUMOylation after the
over-expression of the tagged form
of SUMO1.
Used to observe cellular and viral
proteins that are targeted by
SUMO1 during Influenza infection
The SUMO1 overexpressed by the
AdV used lacks the di-glycine motif
required for SUMO-conjugation;
Used to observe proteins that are
being purified via SUMO-interacting
motifs after infection, or simply
cross react with our purification
system
Not-infected sample; Used to
observe cellular proteins that are
targeted for SUMOylation after the
over-expression of the tagged form
of SUMO1Q94P
Used to observe cellular and viral
proteins that are targeted by
SUMO1Q94P during Influenza Viral
infection

SDS-PAGE and Immunoblotting
Every total cell extract was collected in either 2x or 4x sample buffer for the
tandem affinity purification samples. Each of the resulting extracts was passed 10 times
through a 291/2 gauche needle to break down chromosomal DNA. Subsequently, βmercaptoethanol was added to the samples with less than 1 M urea up to a final
concentration of 10%. The samples were then boiled for 3 min, and resolved by an inhouse made 7.5% SDS-PAGEs. The gels were run at 175 V (constant voltage), for
either 11/2 or 41/2 h. Upon SDS-PAGE, the proteins were transferred to PVDF
ImmobilonTM-P membranes using a tank-blotting system, at either 1.75 or 2.00 amps
(constant current) for either 65 or 120 min. The membranes were washed three times in
1x PBS solution supplemented with 0.05% Tween-20 (1x TPBS), blocked in 1x TPBS
supplemented with 3% non-fat milk (1x Blotto) for 1 h at room temperature, and
subsequently incubated with primary antibody diluted down to the indicated dilution in
1x Blotto over night at 4°C. The membranes were washed three times with 1x TPBS,
and incubated with secondary antibody at the indicated dilutions for 1 h. Finally, the
membranes were washed three times with 1x TPBS, and developed using the
ImmobilonTM Western HRP Substrate system (Millipore). In most experiments the
membranes were re-used. Before re-use, the ImmobilonTM membranes were stripped by
incubation in boiling stripping buffer (3% SDS and 0.3% β-mercaptoethanol) for 10 min,
and washed five times with 1x TPBS.
The following primary and secondary antibodies, at the indicated dilutions, were
used throughout this experiments: anti-SUMO1 rabbit MAb Y299 (Epitomics Inc.
Burlingame, CA) at 1:5000 for SUMO1; anti-Influenza A virus NS1 MAb NS1-1A7
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(Biodefense & Emerging Infections Research resources Repository, VA); anti-GAPDH
MAb 2D4A7 (Santa Cruz Biotechnology Inc.); anti-AOS-1 18A (Santa Cruz
Biotechnology Inc.); anti-SAE2 rabbit polyclonal antibodies (Novus Biologicals, LLC,
Littleton, CO) at 1:1000 for SAE2; anti-M1 mouse MAb clone GA2B (Meridian Life
Science, Inc.) at 1:5000 for M1; anti-Ubc9 rabbit MAb EP2938Y (Epitomics Inc.) at
1:5000 for Ubc9; anti-ISG15 rabbit MAb EPR3445 (Epitomics Inc.) at 1:1000 for ISG15;
anti-mouse IgG goat polyclonal antibody HRP-conjugated (Santa Cruz Biotechnology,
Inc.) at 1:5000 for detection of all mouse MAbs; anti-rabbit IgG goat polyclonal antibody
HRP-conjugated (Santa Cruz Biotechnology, Inc.) at 1:5000 for detection of all rabbit
monoclonal and polyclonal antibodies.
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1.3 Results
1.3.A Effects inflicted on the cellular SUMOylation system by influenza A infection.
Influenza A virus upregulates the cellular SUMOylation system upon infection. Our
previous work had identified NS1 as a viral target for the cellular SUMOylation system,
thus indicating an interaction between this system and Influenza A virus during infection.
However, it was unknown whether viral infection had any effected on cellular
SUMOylation.

To

determine

whether

Influenza

A

infection

affected

cellular

SUMOylation, HEK293A cells were infected with influenza A/PR/8/34 and A/Vic/77 at a
multiplicity of infection (MOI) of 5 and collected at multiple times post-infection. The
panel A in figure 1.A.1 shows that the total pool of SUMOylated proteins of high
molecular weight increases as viral infection progresses. The increase in SUMOylation
observed after infection is accompanied by the appearance of three new SUMOylated
proteins of molecular weights of ~37, 50, and 75 kDa. Interestingly, panels B-D in figure
1.A.1 also indicate that the increase in cellular SUMOylation is not mediated by a
change in the levels of any of the enzymes involved in the SUMOylation pathway.

Quantification of the increase in cellular SUMOylation during influenza A infection. After
we determined that SUMOylation is increased during influenza A infection with multiple
viral strains (H1N1 A/PR/8/34; H1N1 A/WSN/1933; H3N2 A/Vic/77) and cells lines
(Madine Derby Canine Kidney (MDCK); Human Embryonic Kidney 293A (HEK293A);
A549; Vero), our next goal was to perform an assay that would allow us to quantify the
observed increase in overall SUMOylation. To do so, the same set of samples collected
at 12h post-infection for the experiment shown in figure 1.A.1, were used to quantify the
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increase in cellular SUMOylation observed after influenza A infection. Figure 1.A.2
compares the 12h mock infected total cell extract to serial dilutions of the 12h infected
total cell extract. The infected sample in this figure is depicted as percentages, which
represent serial dilutions of the extract with 2x sample buffer to obtain the indicated
values on the top row. This approach allows for a semi-quantitative analysis of the
increase in cellular SUMOylation after viral infection by simply using immunoblotting
techniques and unaided visual analysis. We concluded that the amount of total
SUMOylated proteins doubles at 12 h post-infection, since the intensity shown in the
SUMO1 immunoblot for the mock-infected sample seems to have less than the 60%
dilution of the infected sample, but more than the 40% dilution. This indicates that there
is a two-fold increase in the total amount of SUMOylated proteins during influenza
infection.
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Figure 1.A.1- Effects of Influenza A infection on the cellular SUMOylation system.
(A-F) Total cell extracts collected at different times post-infection in 2x sample buffer of
infected HEK293A cells using Influenza H1N1 A/PR/8/34 and Influenza H3N2 A/Vic/77 at a
multiplicity of infection (MOI) of 5. Extracts were resolved by SDS-10% PAGE gel, and blotted
into a PVDF-membrane for immunoblotting. Sizes of protein standards (Bio-Rad) are shown
on the left in kilodaltons together with the antibodies used in each immunoblot depicted. Lane
1 shows a sample transfected with a bicistronic construct expressing a His- and S-tagged
form of SUMO1 and an HA-tagged form of Ubc9. Lanes 2 and 6 show mock-infected samples
collected at 12h post-treatment for direct comparison with the infected samples also collected
at the same time post-infection.

35

Figure 1.A.2- Quantification of the increase in cellular SUMOylation of cells infected with
Influenza A virus.
(A-C) Total cell extracts of either mock-infected or infected HEK293A cells were collected 12h
post-infection in 2x sample buffer. Infection was done by using Influenza H1N1 A/PR/8/34 at a
MOI of 5. The mock-infected extracts were incubated with 1x DMEM supplemented with 0.2%
BSA. For direct comparison between the infected and the non-infected samples serial
dilutions of the infected extract were made to achieve the indicated percentages shown on the
top row. Sizes of protein standards (Bio-Rad) are shown on the left in kilodaltons together with
the antibodies used in each immunoblot depicted.
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The increase in SUMOylation can only be triggered by a transcriptionally active
influenza A virus. Next, we wanted to determine the cellular mechanism mediating this
increase in SUMOylation observed after infection. At first we hypothesized that this
might be an antiviral mechanism, which is activated during a type I interferon response.
So in order to determine if this was the case, we treated both HEK293A and A549 cells
with recombinant IFN-β and compared their SUMO1 profile to that of infected total cell
extracts. As shown in figure 1.A.3, even though, the interferon response was substantial
enough as to enable us to detect ISG-15 by immunoblotting, we were not able to
observe any visible change in the SUMO profile. Therefore, indicating that this was not
a cellular mechanism activated by a type I interferon response. Next, we speculated that
a signaling cascade might be activated upon attachment of viral antigens to a cell
surface or cytoplasmic receptor, which can then trigger the increase in cellular
SUMOylation observed. To address this question we exposed the same volume of
influenza H3N2 A/Vic/77 used for an infection with an MOI of 5 to U.V. irradiation to
render it transcriptionally inactive. The U. V. treatment proved to be successful at
inactivating the viral particles, as supported by the lack of production of the M1 protein
as assessed by immunoblotting. However, the cells treated with the inactivated virus
also exhibited no change in the SUMO profile. This led us to conclude that in order to
have an increase in cellular SUMOylation you require a transcriptionally active Influenza
A virus.
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Figure 1.A.3- The increase in SUMOylation is not mediated by an interferon type I
response and requires a transcriptionally active form of Influenza A virus.
A549 cells (A) or HEK293A cells (B) were infected either with active Influenza H3N2 A/Vic/77
at an MOI of 5, UV-inactivated Influenza H3N2 A/Vic/77 at an MOI of 5, or treated with
1000U/mL of purified recombinant IFN-β. The total cell extracts were collected in 2x sample
buffer at the indicated times post-infection, resolved by SDS-PAGE, and blotted against a
PVDF-membrane to be analyzed by western blotting. The M1 antigen was used to determine
the presence of a transcriptionally active Influenza A virus. The ISG-15 antigen was used to
determine if the cells were stimulated due to the addition of recombinant IFN-β. Sizes of
protein standards (Bio-Rad) are shown on the left in kilodaltons together with the antibodies
used in each immunoblot depicted.
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The cellular population adjacent to the infected cells is overexpressing SUMO1 during
influenza a virus infection. After demonstrating that the increase in SUMOylation
happened only in cells infected with a transcriptionally active influenza virus, we wanted
to determine which cell population was experiencing this increase in SUMOconjugation. This data would provide cues as to whether this is an antiviral mechanism
or a cellular process required for efficient viral replication. We decided to address this
question through a time point experiment and confocal microscopy as it is shown in
figure 1.A.4. Briefly, A549 cells were infected with influenza H1N1 A/WSN/1933 at an
MOI of 10, and processed for IFA as described in materials and methods. DAPI was
used to stain the nucleus, and a mouse monoclonal antibody against the late viral
antigen M1 was used as a maker to differentiate between the infected and non-infected
cell populations. Surprisingly, the cells experiencing a robust increase in SUMOylation
at late stages of infection turned out to be those surrounding the cells expressing the
M1 antigen. However, after quantifying the signal intensities for the accumulation of
nuclear SUMO1, we also observed that the increase in cellular SUMOylation happened
in both the infected and non-infected populations but only at early time points postinfection. These results suggest that the cells progressing to late stages of infection are
the ones that exhibit a decrease in overall SUMOylation.

The infected cells also have an increase in SUMO1 expression at early stages of
infection. With this in mind, we decided to perform a similar experiment, but using the
early viral antigen NS1 to identify cells at an early stage of infection. In this experiment
we also quantified the nuclear accumulation of NS1, in order to differentiate between
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cells at different stages of infection. The results shown in figure 1.A.5 suggest that
indeed, some cells at an early stage during infection are also experiencing an increase
in cellular SUMOylation, which at some point during infection stops and starts declining.
We came to this conclusion since 10% of the total population of cells expressing the
NS1 protein experienced an increase in SUMOylation at both early (12 hours) and late
(24 hours) stages of infection. Altogether, these results indicate that SUMOylation is
upregulated upon infection with influenza A virus in both infected and surrounding noninfected cells, and the progression to late stages of infection appears to require a
subsequent downregulation of the SUMO system. Nonetheless, additional experiments
are needed to determine the molecular mechanism behind this seemingly tightly
orchestrated cellular antiviral response.
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Figure 1.A.4- The increase in SUMOylation is happening on cells adjacent to cells in
late stages of infection.
A549 cells were either infected with Influenza A/WSN/1933 by using an MOI of 10 or mock
infected by incubating with 1xDMEM + 0.2% BSA. The cells were processed for
immunofluorescent analysis at the indicated times post-infection, using anti-SUMO1MAb, antiM1 MAb and DAPI stain. The Images were captured using an LSM 700 confocal microscope
(Zeiss, New york, NY) with a 63X objective and three lasers at 405 nm (DAPI), 488 nm (antiM1), and 555 nm (anti-SUMO1). ZEN 2009 software (Zeiss, New york, NY) was used for the
acquisition and processing of the confocal images.
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Figure 1.A.5- The increase in SUMOylation is also taking place in infected cells at early
stages of infection.
A549 cells were either infected with Influenza A/WSN/1933 by using an MOI of 10 or mock
infected by incubating with 1xDMEM + 0.2% BSA. The cells were processed for
immunofluorescent analysis at the indicated times post-infection, using anti-SUMO1MAb, antiNS1 MAb and DAPI stain. The Images were captured using an LSM 700 confocal microscope
(Zeiss, New york, NY) with a 63X objective and three lasers at 405 nm (DAPI), 488 nm (antiNS1), and 555 nm (anti-SUMO1). ZEN 2009 software (Zeiss, New york, NY) was used for the
acquisition and processing of the confocal images
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1.3.B. Identification of the proteins targeted by the cellular SUMOylation system after
viral infection

Multiple cellular and influenza A proteins are SUMOylated during viral infection. After
characterizing the effects that Influenza A infection inflicted on the cellular SUMOylation
system, we wanted to identify the cellular and viral proteins that are targets for SUMOconjugation during infection. This question is of great relevance, since it might lead to
the discovery of cellular or viral proteins whose SUMOylation is indispensable for viral
replication, therefore, bringing about new targets for the development of antiviral
therapies. In order to identify these SUMOylated proteins, we used a tandem affinity
purification method described in Rosas-Acosta et. al., 2005, which utilizes a His- and Sprotein N-terminally tagged form of SUMO1 overexpressed from a bicistronic construct
together with an HA-tagged form of Ubc9. However, the methodology employed in the
current study was slightly different, since the overexpressed gene was delivered to the
targeted cells via a recombinant adenovirus vector instead of a transfected expression
plasmid. The reason for making this change was because the cell line used in this study
(A549 cells) has really low transfection efficiencies, so by using a recombinant
adenoviral vector we could increase the percentage of cells that would be
overexpressing this bicistronic construct at the time of infection. After following the
modified methodology, we collected fractions of each sample along the multiple steps in
the tandem affinity purification to ensure that SUMOylated proteins were being
separated from the pool of non-SUMOylated cellular proteins. Panel A from figure 1.B.1
demonstrates that SUMOylated proteins were captured in both the Ni-NTA beads and
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S-protein beads. Panel B from the same figure shows that Influenza infection
progressed accordingly in the presence of all the recombinant adenoviruses by the
detection of the NS1 viral protein. Also, it indicates that viral proteins were present
among the pool of SUMOylated proteins along every step of the tandem affinity
purification. The fact that NS1 was detected by immunoblotting in its non-SUMOylated
form indicates that additional cellular proteins such as SUMO-deconjugating enzymes,
which are known to be SUMO targets, might be present among the pool of SUMOylated
proteins and actively cleaving SUMO from the purified proteins. Furthermore, the fact
that NS1 is not detected by immunoblot in its non-SUMOylated form in the S-protein
beads when transduced with the non-deconjugatable form of SUMO1 (SUMO1Q94P),
but is present in the mass spectrometry data as a high confidence peptide in the same
sample, indicates that there was only SUMO-conjugated NS1 in this sample. From the
pool of viral proteins identified in this mass spectrometry study, we detected and
identified two viral proteins who are bona-fide SUMO targets; Non-structural 1 (NS1)
and Matrix 1 (M1) proteins. The fragmentation patterns for both of these viral peptides
are shown in figure 1.B.2, and were identified as high confidence peptides, as indicated
in table 1.B.2. The other four viral peptides identified in this study were identified as low
confidence peptides that started and ended in tryptic cleavage sites. Additionally, some
of these viral antigens were already identified as targets for SUMO-conjugation in the
published manuscript by Pal et. al in 2010. However, this experiment needs to be
repeated in order to fully assess the validity of these identified viral and cellular SUMO
targets.

44

Figure 1.B.1- Western blot analysis of the samples processed by using the Tandem
affinity purification for mass spectrometry.
A549 cells were transduced with the indicated recombinant adenoviruses to overexpress the
SUMO conjugating enzyme Ubc9 and different SUMO1 mutants at an MOI of 100. 48 h posttransduction they were infected with Influenza H1N1 A/WSN/1933 at an MOI of 10. 30 h postinfection the samples were collected in an 8M urea denaturing buffer and processed by
tandem affinity purification. Different extracts were collected at several stages along the
purification in 4x sample buffer, resolved by SDS-PAGE, blotted into PVDF membranes, and
analyzed by immunoblotting. (A-B) Immunoblots of the different cell extracts collected
throughout the tandem affinity purification process and directed against the indicated epitopes.
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Table 1.B.1- Cellular proteins identified to be SUMOylated during influenza A viral
infection.
Table showing the cellular proteins identified in the mass spectrometry analysis as SUMO
targets after influenza A infection. All proteins identified were present in the analysis as low
confidence peptides except for SUMO1, but represent only the pool of proteins with peptides
starting and ending in tryptic cleavage sites. The predicted SUMOylation sites were
determined by using the SUMOsp 2.0 software under a high stringency threshold.
Accession #

# of
SUMO
Sites

Aconitase 1
variant

Q59FI0

1

ERVPLLGSGSPVAGAPPCSR

Unknown

Apolipoprotein B

C0JYY2

11

LDVTTSIGR

Lipid
transporter

Breast cancer
type 2
susceptibility
protein

P51587

9

FEVSSASNAQTR

DNA repair

Cyclin-T2

O60583

3

NIISSTALFLAAK

EPC1/ASXL2b
fusion protein

B8XCX8

9

APSPTGPALISGASPVHCAADGTV
ELK

Q86XX4

1

FEVSSASNAQTR

Cell Adhesion

Q2KHR3

8

TSQVSVELAQSYSSAIPSSGYPPS
TTK

Unknown

Q96RW7

9

YVCVAVNVAGMTDKK

Unknown

A2BDK6
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SPSLSPSPPSPLEK

Cell structure
regulator

NAV2 protein

A7E2D6

5

KQSGSAAGLAMITASGVTVTSR

Plexin-B2

O15031

1

SKSCVAVTSAQPQNMSRR

Protein furry
homolog-like

O94915

8

SDSMPLYSNWR

Protein SZT2

Q5T011

2

AILASESSIETEDLSEPEFQSTR

Putative
uncharacterized
protein
DKFZp451P0217

Q86TE3

2

LSSSSPGATVSPSSSDAEYDK

Protein Name

Extracellular
matrix protein
FRAS1
Glutamine and
serine-rich protein
1
Hemicentin-1
Microtubuleassociated protein
1B

Peptide Sequence
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Function

Transcriptional
regulation
Negative
Transcriptional
Regulator

Cell structure
regulator
Cell structure
regulator
Cell structure
regulator
Oxidative
Stress
Unknown

Sickle tail protein
homolog
Single-minded
homolog 1
Solute carrier
family 19 (Folate
transporter)
Spectrin-like
protein of the
nuclear envelope
and Golgi
StAR-related lipid
transfer protein 9
SUMO1*
Uncharacterized
protein

Q5T5P2

7

APPPLSFSSSPPSPASSVSLNQGA
K

Cellular
development
Transcription
factor

P81133

1

NYSLGCNGSHFDVTSHLR

D3DSM6

1

GLSRMVPSSPAVEK

Thymine
transporter

Q7RTM4

27

QNTTASGCELMHTEMQALR

Unknown

Q9P2P6

9

NACHSNVTTATK

Lipid
transporter

2

VQTQVRLAKK

Unknown

P63165
B9ZVM7
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Table 1.B.2- Viral proteins identified to be SUMOylated during influenza A viral infection.
Table showing the viral proteins identified in the mass spectrometry analysis as SUMO targets
after influenza A infection. Sample marked with * indicates that the SUMOylation sites were
determined under low stringency. Samples marked with ** were present in the analysis as
high confidence peptides. The predicted SUMOylation sites were determined by using the
SUMOsp 2.0 software under a high stringency threshold.

Accession #

# of
SUMO
Sites

Peptide Sequence

NS1**

gi94156

1

NAVGVLIGGLEWNDNTVR

M1**

gi157460211

2

NTDLEALMEWLK

NP

gi14326109

2*

SYEQMETDGER

PB1

gi159139246

3

KMMTNSQDTELSFTITGDNTK

PB2

gi151177063

3

DSSILTDSQTATK

PB1-F2

gi212381558

1

MGQEQGTPWIQSTGHTSTQK

Protein
Name
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A

M1

B

NS1

Figure 1.B.2- Proteomic analysis of the TAP-Purified samples obtained from transduced
A549 Influenza A infected cells.
Fragmentation patterns of two viral proteins identified in the MS/MS proteomic analysis of the
TAP-purified proteins. A) Matrix 1 (M1) protein. B) Non-structural 1 (NS1) protein.
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1.3.C. Partial characterization of the effects of SUMO-conjugation on the Non-Structural
1 (NS1) viral protein
The cellular localization of NS1 is not affected by SUMOylation. Since we were capable
of identifying two viral proteins as bona fide SUMO targets through our proteomic
approach, we went ahead and assessed the functionality of SUMO-conjugation on one
of the viral proteins identified, namely NS1. Previously, our laboratory had mapped two
lysine residues at positions 219 and 70 as the main SUMOylation sites in the NS1
protein. Given that SUMOylation is known to affect the cellular localization of many
proteins, we first decided to determine if SUMOylation had any effect on the cellular
localization of NS1. In order to do so, we performed transfection experiments to
overexpress and compare the cellular distribution of a T7-tagged wild type NS1 protein
(T7T7NS1)

to

that

of

a

T7-tagged

non-SUMOylatable

NS1

protein

(T7T7NS1K70AK219A) bearing lysine to alanine substitutions at amino acids in
positions 219 and 70. Furthermore, we also evaluated the effects of hyper-SUMOylating
the NS1 protein through the use of a protein chimera composed of the RNA-binding
domain of NS1 fused to the SUMO-conjugating enzyme Ubc9. This protein fusion,
referred to as the Artificial SUMO-ligase (ASL), has been previously shown to exploit
the dimerization properties of NS1 to bring Ubc9 into close proximity to the main
SUMOylation site at lysine 219 and specifically hyper-SUMOylate the NS1 protein.
Looking at the effects of hyper- or hypo-SUMOylating the NS1 protein, gives us a less
biased approach to determine if SUMOylation is playing any role in the localization of
NS1. To this end, all of these proteins were expressed by transient transfection of
HEK293FT cells, and the cellular distributions of the different NS1 proteins was
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assessed 24 hours post-transfection by confocal microscopy. Once again we utilized
DAPI to delineate the cells nuclei, and a mouse monoclonal antibody against the T7epitope to evaluate the cellular distribution of NS1. Under the conditions tested the
results indicate that SUMOylation is not playing any role in the cellular distribution of
NS1, since both the T7T7NS1 and T7T7NS1K70AK219A have very similar cellular
localizations as shown in figure 1.C.1. Nevertheless, the cellular distribution of the NS1
protein might not seem to be affected under these conditions, since no other viral
factors are present in the cell in these experiments. Hence, to further assess if
SUMOylation affects the localization of NS1 in the presence of other viral antigens, we
decided to transiently transfect an influenza A reverse genetics system to recreate
conditions similar to those of viral infection. After evaluating both the hyper- and hypoSUMOylation of the NS1 protein in the presence of the all the other viral proteins shown
in figure 1.C.2, we concluded that SUMOylation does not play a role in the cellular
localization of the NS1 protein.
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Figure 1.C.1- SUMOylation does not affect the cellular localization of NS1.
HEK293FT cells were transfected with either the T7T7NS1 or the T7T7NS1K70AK219A
construct, alone or in the presence of the ASL to ensure the evaluation of any potential
effect imposed by SUMOylation on the cellular distribution of NS1. Immunofluorescent
analyses were performed as described in materials and methods, using anti-T7 MAb,
anti-Ubc9 MAb, and DAPI stain. The images were captured using an LSM 700 confocal
microscope (Zeiss. New York, NY) with a 63X objective and three lasers at 405 nm
(DAPI), 488 nm (anti-T7), and 555 nm (anti-Ubc9). ZEN 2009 software (Zeiss. New
York, NY), was used for the acquisition and processing of the confocal images.
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Figure 1.C.2- SUMOylation does not affect the cellular localization of NS1 in conditions
recreating viral infection through the use of an influenza A reverse genetics system.
HEK293FT cells were transfected with an Influenza H1N1 A/WSN/1933 reverse
genetics system together with either the T7T7NS1 or the T7T7NS1K70AK219A
constructs. The reverse genetics system will be co-transfected alone or in the presence
of the ASL to ensure the evaluation of any potential effect imposed by SUMOylation on
the cellular distribution of NS1.

Immunofluorescent analyses were performed as

described in materials and methods, using anti-T7 MAb, anti-Ubc9 MAb, and DAPI
stain. The images were captured using an LSM 700 confocal microscope (Zeiss. New
York, NY) with a 63X objective and three lasers at 405 nm (DAPI), 488 nm (anti-T7),
and 555 nm (anti-Ubc9). ZEN 2009 software (Zeiss. New York, NY), was used for the
acquisition and processing of the confocal images.
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SUMOylation affects the formation of NS1 dimers and trimers. An additional role of
SUMO-conjugation is to provide a docking site that brings about additional molecular
interacting partners. Therefore, by doing so SUMOylation can regulate the proteinprotein interactions established by the modified protein. In order to evaluate if
SUMOylation is affecting the protein-protein interactions established by NS1, we
overexpressed the T7T7NS1 and the T7T7NS1K70AK219A either in the presence or
absence of the ASL. To prevent the disruption of the protein-protein interactions
established by NS1, 24 hours post-transfection we treated the cells with the cell
permeable homobifuncional crosslinker disuccinimidyl glutarate (DSG). DSG forms a
stable covalent amide bond by targeting amine groups of proteins that are 7.7 Å apart.
To assess the protein complexes formed, the crosslinked total cell extracts were
analyzed by SDS-PAGE followed by immunoblotting with antibodies against the T7epitope present at the N-terminus of the different NS1 proteins. As shown in figure
1.C.3, SUMOylation prevents the dimerization or trimerization of the NS1 protein, since
the abundance of these complexes is increased when the non-SUMOylatable form of
NS1 is overexpressed. The formation of these NS1 complexes is essential for the NS1’s
ability to prevent the recognition of viral RNA during infection. Therefore, these results
suggest that the SUMOylation of NS1 might decrease its IFN blocking activity during
infection.
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Figure 1.C.3- NS1 SUMOylation affects the abundance of NS1 dimers and trimers.
HEK293FT cells were co-transfected with (+) or without (-) the indicated mammalian
expression constructs. 24 hours post-transfection, the cells were treated with either
1mM disuccinimidyl glutarate or with vehicle only. Half and hour later, the cells were
collected and analyzed by SDS-PAGE and immunoblotting using the indicated
antibodies. NS1SUMO: SUMOylated NS1. The position of the NS1 dimers and trimers is
indicated and emphasized by diagonal arrows.
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1.4 Disccusion
Influenza A virus as previously demonstrated by other groups and in the
experiments described above interacts extensively with the cellular SUMOylation
system during infection [85, 92-94]. The triggering of a robust increase in cellular
SUMOylation in cells adjacent to those infected by influenza virus suggests that
SUMOylation may act as an antiviral cellular response. Nonetheless, since this
phenomenon is not triggered by a recombinant IFN-β treatment or by the addition of U.
V. inactivated viral particles, it is indicative that we might have come across a novel and
uncharacterized IFN-β- and TLR-independent anti-viral response.
However, the interaction between SUMOylation and influenza seems to be far
more complex. Several studies have previously identified multiple components of the
SUMO cascade as essential cellular factors for influenza replication. This idea is also
supported by the confocal images showing an increase in SUMOylation in cells at an
early stage of infection, and by the fact that this phenomenon is triggered by multiple
strains of Influenza A virus. Recent unpublished data gathered in our laboratory show
that the new SUMOylated products of molecular weight of 50 kDa are neither IRF-3 nor
IRF-7 (data not shown), as it is the case during Ebola virus and Vesicular Stomatitis
virus infection, signifying that this is an uncharacterized viral mechanism to inhibit
cellular antiviral responses [89, 97].
Therefore, is imperative to identify and characterize the cellular and viral proteins
that are SUMOylated during infection for determining how influenza is being benefited
or affected by SUMO. Consequently, the identification of these cellular proteins whose
SUMOylation is essential for viral replication will open multiple new areas of research
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that might lead to the development of novel antiviral therapies. These new therapies will
have the advantage of targeting a cellular factor for which the virus has no control over,
and will have the unique characteristic of being effective against every strain of
influenza A virus. Altogether, further characterization of this complex interplay is needed
in order to determine if this increase in cellular SUMOylation is beneficial or detrimental
for viral replication.
Lastly, since there are two sides to the interplay between SUMOylation and
influenza, this study also identifies viral proteins that are SUMOylated during infection,
namely NS1 and M1. As mentioned above, the role of SUMOylation for M1 has been
extensively studied and characterized, and thanks to these studies now we have
important cues as to what is the role of NS1 SUMOylation [91, 98]. As shown above,
SUMOylation seems to be affecting the IFN-blocking activity of NS1 by preventing the
formation of NS1 complexes that coat viral RNA during infection. However, we cannot
limit the function of NS1 SUMOylation to only this, since preventing the formation of
these complexes might be important for dictating the fraction of the NS1 population
available to establish additional protein-protein interactions. This fraction of NS1 may be
important for the execution of the additional roles played by NS1 during infection. As for
the rest of the viral proteins identified in this study the role of SUMOylation remains to
be elucidated. The characterization of the effects of this post-translational modification
on each of these viral proteins will allow further understanding of the viral life cycle, and
can also lead to the development of new antiviral therapies.
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CHAPTER 2: THE IDENTIFICATION OF THE POLYMERASE BASIC 1 (PB1) VIRAL
PROTEIN AS A BONA FIDE SUMO TARGET AND CHARACTERIZATION OF THE
EFFECT OF SUMO-CONJUGATION ON THE VIRAL POLYMERASE DURING
INFLUENZA A INFECTION
2.1 Introduction
PB1 is a critical component of the influenza viral polymerase, since it is the
subunit containing the RNA-dependent RNA-polymerase (RdRp). Stephen C. Inglis
from the University of Cambridge at England first discovered that the Influenza viral
polymerase was a heterotrimeric complex composed of PB1, PB2, and PA in the
1970’s. Ever since, the characterization of each individual subunit has provided
substantial information contributing to our knowledge of the mechanisms employed by
the virus for transcription and replication. As of today, PB1 is known as the constituent
of the viral polymerase bearing the ability to recognize the viral promoters located at the
3’ and 5’ ends of each viral gene segment. Also, PB1 has the ability to transcribe and
replicate the viral genome when it interacts with PB2, PA, and NP forming a functional
RNA-dependent RNA-polymerase. Even though its characterization has been thorough
enough as to map most of the amino acid sequences involved in protein-protein
interactions and RNA-binding domains, none of the studies performed in the past
involved the characterization of the effects imposed by any cellular post-translational
modifications on this viral protein.
Our previous studies show that PB1 is modified by a cellular post-translational
modification called SUMOylation, when overexpressed in cellular environments of
upregulated SUMOylation achieved by transfection [85]. Moreover, PB1 was also
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identified among the pool of SUMOylated proteins during infection in cells
overexpressing SUMO1 and the E2 SUMO-conjugating enzyme Ubc9 by using
recombinant adenoviral vectors [85]. Nonetheless, given SUMO-conjugation can have
multiple effects depending on the modified target ranging from affecting cellular
localization, catalytic activity, and protein-protein interactions, the characterization of
each target individually is empirical in determining its role upon conjugation.
Furthermore, since this post-translational modification may play an essential role in
regulating the activity of this key viral protein, it is of great relevance to characterize the
effects of SUMOylation on the viral protein PB1.
Intriguingly, PB1 has three possible SUMOylation sites predicted under a high
stringency test by using the SUMO predictor software SUMOsp 2.0 [99]. Two of these
predicted SUMO acceptor sites exist within classical SUMO consensus motifs.
However, a degree of variation exists among the amino acid sequence of PB1
throughout different influenza A strains. So, in order to determine if these three lysine
residues are highly conserved among different viral strains, more than 3000 amino acid
sequences of different PB1 proteins from multiple strains of influenza A virus obtained
from the Influenza Research Database were analyzed. The results are depicted in table
2.1 and indicate that all three lysine residues are very well conserved in H1N1, H3N2,
and H5N1 viruses. With this in mind, this study was designed to provide experimental
evidence that PB1 is a bona fide SUMO target and on the characterization of the effects
inflicted by SUMO-conjugation on the influenza viral protein PB1. Our goal is to map its
SUMOylation sites and determine if SUMOylation of PB1 has any effect on its cellular

59

localization, transcriptase and replicase activity, or ability to efficiently bind to viral
promoters.
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Table 2.1- Predicted SUMOylation sites by SUMOsp 2.0 on the viral protein PB1.
Table showing the predicted SUMOylation sites for PB1 by using SUMOsp 2.0 and the
percentage of viral strains bearing the SUMO acceptor Lysine residue at the indicated
positions. (2019 amino acid sequences were analyzed for H1N1; 999 amino acid sequences
were analyzed for H3N2; 192 amino acid sequences were analyzed for H5N1; all viral strains
analyzed were from isolated viruses from 1990-2011 and were obtained from the Influenza
Research Database http://www.fludb.org)
Conserved
Position

Sequence

Type
H1N1

H3N2

H5N1

175

SMNKEEM

75.4%

99.9%

99%

Non-consensus

611

VCLKWEL

99.9%

99.9%

99%

?-K-X-E

735

GRIKKEE

90.4%

99.9%

99%

?-K-X-E
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2.2 Materials and methods
Mammalian cell cultures
HEK293FT (ATCC, Manassas, VA), were maintained in 1x Dubelcco’s modified
essential medium (DMEM) supplemented with high glucose, L-glutamine, sodium
pyruvate, and 10% fetal bovine serum. The cells were maintained in a 37°C incubator at
5% CO2, and split every 48 h at a 1:5 ratio.

SDS-PAGE and Immunoblotting
Every total cell extract was collected in either 2x sample buffer or 4x sample
buffer. Each of the resulting extracts was passed 10 times through a 291/2 gauche
needle to break down chromosomal DNA. Subsequently, β-mercaptoethanol was added
up to a final concentration of 10%, the samples were then boiled for 3 min, and resolved
on either a 7.5% or 10% SDS-PAGE gel made in-house. The gels were run at 175 volts
(constant voltage), for 41/2 h. Upon SDS-PAGE resolution, the proteins were transferred
to PVDF ImmobilonTM-P or PVDF ImmobilonTM-FL membranes using a tank-blotting
system, at 2.00 amps (constant current) for 120 min. The membranes were washed
three times in 1x phosphate buffer saline (PBS) solution supplemented with 0.1%
Tween-20 (1x TPBS), blocked in 1x TPBS supplemented with 3% non-fat milk (1x
Blotto) for 1 h at room temperature, and subsequently incubated with primary antibody
diluted down to the indicated dilution in 1x Blotto over night at 4°C. The membranes
were washed three times with 1x TPBS, and incubated with secondary antibody at the
indicated dilutions for 1 h. Finally, the membranes were washed three times with 1x
TPBS, and developed using the ImmobilonTM Western HRP Substrate system (Millipore)
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or analyzed by the Odyssey Infrared Imaging System Application software version
3.0.29 (LI-COR) Biosciences Inc.). Statistical analyses and graphics of the data
generated were performed by using Graphpad Prism version 5.04 for Windows
(GraphPad Software Inc.). In most experiments the membranes were re-used. Before
re-use, the ImmobilonTM membranes were stripped by incubation in boiling stripping
buffer (3% SDS and 0.3% β-mercaptoethanol) for 10 min, and washed five times with 1x
TPBS.
The following primary and secondary antibodies, at the indicated dilutions, were
used throughout this experiments: anti-SUMO1 rabbit MAb Y299 (Epitomics Inc.
Burlingame, CA) at 1:5000 for SUMO1; anti-GAPDH MAb 2D4A7 (Santa Cruz
Biotechnology Inc.); anti-SUMO2 rabbit polyclonal antibodies (Invitrogen Corp.) at
1:5000 for SUMO3; anti-GFP (B-2) mouse MAb (Santa Cruz Biotechnology, Inc.) at
1:5000 for PB1-GFP; anti-AOS-1 18A (Santa Cruz Biotechnology Inc.); anti-SAE2 rabbit
polyclonal antibodies (Novus Biologicals, LLC, Littleton, CO) at 1:1000 for SAE2; antiUbc9 rabbit MAb EP2938Y (Epitomics Inc.) at 1:5000 for Ubc9; anti-SENP1 rabbit MAb
EPR3844 (Epitomics Inc.) at 1:5000 for SENP1; anti-mouse IgG goat polyclonal
antibody HRP-conjugated (Santa Cruz Biotechnology, Inc.) at 1:5000; anti-rabbit IgG
goat polyclonal antibody HRP-conjugated (Santa Cruz Biotechnology, Inc.) at 1:5000;
highly cross-absorbed IRDye 800 CW-conjugated goat anti-rabbit IgG at a 1:20,000
dilution; highly cross-absorbed IRDye 680 LT-conjugated goat anti-rabbit IgG at a
1:20,000 dilution (all IRDye-conjugated antibodies were obtained from LI-COR
Biosciences Inc.).
Transfections
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The bicistronic constructs used in these experiments are pcDNA5/FRT/TO/His-SSUMO1/IRES/Ha-Ubc9, and pcDNA5/FRT/TO/His-S-SUMO2/3/IRES/Ha-Ubc9. Both of
these constructs are described in detail in S. Pal 2010. The plasmids expressing the
GFP C-terminally tagged forms PB1, and FLAG C-terminally tagged forms of PA and
PB2 were kindly provided by Dr. Irving Fodor (Sir William Dunn School of Pathology,
University of Oxford, UK). All transfections were performed using TransIT®-LT1
transfection reagent (Mirus Bio LLC, Madison, WI) following the manufacturer’s
protocol.

Recombinant Adenoviruses
Recombinant adenoviruses were developed by using the ViraPowerTM Adenoviral
Gateway® Expression System. Bicistronic constructs present in a pENTR1A donor
plasmid coding for a His-S-tagged form of SUMO1 and an HA-tagged form of Ubc9
were cloned into the pAd/CMV/V5-DEST destination plasmid. Cloning required
incubation in a recombination reaction by using Gateway® LR clonase II enzyme. The
insertion was confirmed by restriction analysis. The pAd/CMV/V5-DEST plasmid
allowed for recombinant adenoviruses to propagate after Pac I digestion and
transfection into HEK293A cells. For viral propagation the methodology mentioned in
Luo et al. 2007 was followed [95]. All the recombinant adenoviruses mentioned in this
study were created in the same way but they express either EGFP (AdV-EGFP),
bicistronic constructs coding for a mutated form of His-S-SUMO1Q94P bearing a
glutamine to proline substitution at position 94 that renders this mutant nondeconjugatable and HA-Ubc9 (AdV-Dual S1Q94P/I/U), a mutated form of His-S-
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SUMO1ΔGG lacking the di-glycine motif required from SUMO-conjugation and Ubc9
(AdV-Dual S1ΔGG/I/U) or the dominant negative form of Ubc9 and a SUMOdeconjugating enzyme from yeast Ulp1 (AdV-Dual Ubc9C93S/I/Ulp1). Titers for the
recombinant adenoviruses were determined by a spot assay using an anti-hexon mouse
MAb (Santa 284 Cruz Biotechnology, Inc.) and the ImmunoPure® metal enhanced DAB
substrate kit (Pierce Protein Research Products, Thermo Fisher 286 Scientific Inc.
Rockford, IL) as previously reported [96].

Immunofluorescent Assays
For immunofluorescent analysis HEK293FT cells were plated in a 96-well plate
(Black flat bottom) and allowed to reach 70% confluency. Cells were then transfected as
indicated above. The cells were fixed with 1x PBS + 4% Paraformaldehyde 24h posttransfection. Then, the cells were permeabilized by incubating with methanol for 10
mins at 4°C. After permeabilization, the cells were incubated with anti-SUMO1 rabbit
monoclonal (Y299) (Epitomics Inc. Burlingame, CA) at a dilution 1:250, anti-SUMO2
rabbit polyclonal antibody (Invitrogen Corp.) at dilution 1:100, and anti-SENP1 rabbit
monoclonal antibody (Epitomics Inc. Burlingame, CA) at a dilution of 1:250 in 1x PBS
supplemented with 1% goat serum and incubated overnight at 4°C. Excess of antibody
was removed with three washes of 5 minutes each with 1x PBS. Fluorescently labeled
secondary antibodies, namely highly cross-absorbed Alexa fluor® 488 goat anti-mouse
IgG and highly cross-absorbed Alexa fluor® 594 goat anti-rabbit IgG (both from
Molecular Probes®, Life Technologies Corp., Carlsbad, CA) were added to the cells in
1x PBS supplemented with 1% goat serum at a dilution of 1:500 and incubated for 1 h
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at room temperature (RT°). Once again the cells were washed three times with 1x PBS,
then incubated with 4',6-diamidino-2-phenylindole (DAPI) at a concentration of 5 µg/mL
for 5 minutes and washed three additional times with 1x PBS. The images were
captured by using an LSM 700 confocal microscope (Zeiss. New York, NY) with a 63X
objective and three lasers at 405 (DAPI) nm, 488 (Alexa) nm, and 555 (Alexa) nm. The
microscope was assisted by the ZEN 2009 software (Zeiss. New York, NY), designed
for acquisition and processing of confocal images. Since the microscope system is
equipped with monochromatic camera (black and white), we applied computerized (ZEN
2009 software) pseudo color to visualize the fluorescence channels and achieve the
final colored images presented.

Primer Extension Analysis
Total cellular RNA was purified by using the RNeasy mini kit (Quiagen) following
the manufacturer instructions. The total RNA was equalized by the addition of
diethylpyrocarbonate (DEPC)-treated water to each RNA sample after running a 1%
Agarose formaldehyde gel and quantifying signal intensities for the 28S rRNA using the
Gel DocTM system (Bio-Rad). The sequence of the primers used for the detection of viral
RNA (vRNA) and viral messenger RNA (vmRNA) corresponding to the nucleoprotein
(NP) viral gene segment of influenza H1N1 A/WSN/1933, and the mammalian Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) mRNA were the following: NP_PrExt_vRNA: 5’GAAATCATAAGGCTGATGGAAAGTGC -3’ ; NP_PrExt_mRNA: 5'- GGATGTAGAATCGTCCAATTCC -3' ;
GAPDH_PrExt_mRNA: 5’-GAAGGGGTCATTGATGGC-3’. All of the primers used were labeled at
the 5’-end either with an IRDye 700 or IRDye 800 for their detection using Odyssey
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Infrared Imagining system. An equal amount of RNA (~2.5 µg) was incubated with the
primers indicated above and analyzed by using the Primer Extension System - AMV
Reverse Transcriptase (Promega) by following the manufacturer instructions. Lastly, the
IRDye labeled cDNA products were analyzed in 7 M urea 6% acrylamide sequencing
gels by the Odyssey Infrared Imaging System Application software version 3.0.29 (LICOR) Biosciences Inc.). Statistical analyses and graphics of the data generated were
performed by using Graphpad Prism version 5.04 for Windows (GraphPad Software
Inc.).

Radiolabeling and autoradiography
A549 cells were transduced or mock transduced with the recombinant
adenoviruses described in chapter 2 to overexpress the SUMO conjugating enzyme
Ubc9 and different SUMO1 mutants at an MOI of 100. 48 h post-transduction the cells
were infected with Influenza A/WSN/1933 at an MOI of 10. 2 h prior to collection the
cells were starved by adding cysteine and methionine deficient medium (1 x DMEM –
met/-cys) for 1 h. Then, the cells were radiolabeled by adding 0.055 mCi of

35

S

(EasyTag™ EXPRESS35S Protein Labeling Mix, [35S]-, 7 mCi (259MBq), Stabilized
Aqueous Solution; Perkin Elmer, MA) to the medium, and incubating the cells for 1 h at
37° C. following the incubation the supernatant was removed, the cells were washed
with 1x PBS, and the total cell extracts were collected in 2x sample buffer and
processed for immunoblotting.
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2.3 Results
2.3.A. Identification of Polymerase Basic 1 (PB1) as a bona fide SUMO-target
PB1 is SUMOylated by both SUMO1 and SUMO2/3. After determining that the lysine
residues predicted by the SUMOsp 2.0 software were highly conserved among different
viral strains, we decided to assess if PB1 is a bona fide SUMO target. In order to do so,
we recreated an environment were the activity of the cellular SUMOylation system was
upregulated by the transfection of bicistronic constructs overexpressing either SUMO1
or SUMO2/3 together with the E2 SUMO-conjugating enzyme Ubc9 (referred to as Dual
S1/I/U and Dual S3/I/U respectively). Figure 2.A.1 shows that upon overexpression of
PB1-GFP, PB2-FLAG, PA-FLAG together with the Dual S1/I/U or Dual S3/I/U
constructs, an additional band is detected of molecular weight ~210 kDa. To provide
further evidence that this additional band is a SUMOylated form of PB1, some cells
were also co-transfected with a construct overexpressing the SUMO-deconjugating
enzyme SENP1. Given that the overexpression of this SUMO-deconjugating enzyme
caused the band to disappear, it is highly indicative that this protein detected in the antiGFP immunoblot is a poly-SUMOylated form of the PB1 protein.
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Figure 2.A.1- PB1 is SUMOylated when overexpressed by transfection and after
increasing the activity of the SUMOylation system.
HEK293FT cells were co-transfected with (+) or without (-) a GFP-tagged form of PB1 (PB1GFP), a FLAG-tagged form of PA and PB2 (PA-FLAG and PB2-FLAG respectively), the Dual
S1/I/U and Dual S3/I/U, SENP1, and an empty vector to equalize for the amount of DNA
transfected per sample. 24 h post-transfection the total cell extracts were collected in 2x
sample buffer and processed for immunoblotting. (A-D) Immunoblots of the total cell extracts
collected at 24 h post-transfection directed against the specified epitopes.
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2.3.B Effects of SUMOylation on the viral polymerase transcriptase activity
Overexpression of SENP1 has a negative effect on the transcriptase activity of the viral
polymerase. Previous cryo- and negative staining electron microscopy studies of
purified influenza viral polymerases have depicted several different three-dimensional
conformations of the RdRp upon interaction with vRNA, NP, and/or both. Therefore, we
speculate that the addition or removal of a SUMO moiety from the PB1 protein might
lead to an alteration in the three dimensional structure of the viral polymerase as a
whole. There alterations might then have an effect in its two main functions, which are
viral mRNA transcription and viral RNA replication activities. Hence, we went ahead and
determined if the disregulation of the cellular SUMOylation system had any effect on the
transcriptase or the replicase activity of the viral polymerase. To this end, we developed
a reporter encoding the renilla luciferase gene embraced by the 5’- and 3’-untranslated
regions of the NS1 gene segment from influenza H1N1 A/WSN/1933 virus. The
expression of this reporter would be driven by a plasmid containing both human
polymerase I promoter and termination sequences to ensure transcriptional fidelity and
achieve the exact length of the reporter gene. This reporter gene was then used to
study the replicase and transcriptase activities of the viral polymerase in viral
ribonucleoprotein (vRNP) reconstitution assays done by transfection. As shown in figure
2.A.2 there are no changes in the production of the renilla luciferase gene segment
when the activity of the cellular SUMOylation system is enhanced by the bicistronic
constructs Dual S1/I/U and Dual S3/I/U. However, we were able to see decreases in the
levels of the renilla luciferase reporter after transfection of the SUMO-deconjugating
enzyme SENP1. This suggests that SUMOylation might be playing an important role in
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the regulation of viral gene transcription. Interestingly, the overexpression of the
bicistronic construct coding for the dominant negative form Ubc9 and the SUMO
protease from yeast Ulp1 had no effect on the levels of the renilla luciferase reporter. It
is very likely that Ulp1 has different cleavage specificity from that of SENP1, therefore
not having any effect on the SUMOylation of PB1.
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Figure 2.B.1- Decreasing cellular SUMOylation by the overexpression of SENP1 affects
the transcriptase activity of the viral polymerase.
HEK293FT cells were used in the following reconstitution assays shown in the figure
above. The expression of the plasmids encoding for the NS and RLuc genes was driven
under a Polymerase 1 promoter and termination sequences, while the transcription of
the remaining plasmids was driven by a Polymerase 2 promoter. To create hypo- and
hyper-SUMOylation environments during the experiment, the overexpression of SENP1
or the products of bicistronic constructs containing either for SUMO1 or SUMO2/3
together with Ubc9 or the dominant negative form of Ubc9 together with Ulp1 were used
respectively. Samples were collected 48 h post-transfection, analyzed by IR
immunoblotting and quantified by normalizing against the levels of GAPDH using the
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Odyssey LI-COR. Results depicted in the graph on panel C, D, and E are representative
of three independent experiments.
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Overexpression of SENP1 decreases the accumulation of viral mRNA during vRNP
reconstitution assays. Having determined that the transcriptase activity of RdRp is
affected upon the overexpression of the SENP1 protein in vRNP reconstitution assays,
we wanted to confirm that the results observed were not only due to alterations of posttranscriptional regulatory mechanisms. For this purpose, we went ahead and analyzed
the levels of vRNA and vmRNA corresponding to the NP viral protein by similar vRNP
reconstitution assays followed by infrared primer extension analysis. For the primer
extension analysis we used IRDye labeled primers to prevent the usage of radioactively
labeled probes and have an easier and safer methodology available for future
quantification of any type of RNA. As shown in figure 2.B.3 the accumulation of vRNA
does not seem to be affected by increasing or decreasing the activities of the cellular
SUMOylation system, since its accumulation remains relatively constant. On the other
hand, the levels of vmRNA seem to retain a similar pattern to that observed in figure
2.B.2, further supporting the claim that the transcriptase activity of the viral polymerase
is downregulated upon overexpression of the SUMO-deconjugating enzyme SENP1.
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Figure 2.B.2- Decreasing cellular SUMOylation by the overexpression of SENP1 affects
the accumulation of viral mRNA.
HEK293FT cells were used in the following reconstitution assays shown in the figure
above. The expression of the plasmids encoding for the NS and NP genes was driven
under a Polymerase 1 promoter and termination sequences, while the transcription of
the remaining plasmids was driven by a Polymerase 2 promoter. To create hypo- and
hyper-SUMOylation environments during the experiment, the over expression of SENP1
or the products of bicistronic constructs containing either for SUMO1 or SUMO2/3
together with Ubc9 or the dominant negative form of Ubc9 together with Ulp1 were used
respectively. Total RNA was isolated from the cells 18h post-transfection, analyzed by
infrared primer extension analysis and quantified by normalizing against the levels of
GAPDH mRNA using the Odyssey LI-COR.
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Having evaluated the effects that disregulating the cellular SUMOylation system
had on the transcriptase activity of vRdRp through transfection experiments, our next
goal was then to determine if this was also true during viral infection. In order to address
this question, we used the recombinant adenoviruses AdV-EGFP (transduction control),
AdV-Dual S1Q94P/I/U, AdV-Dual S1ΔGG/I/U, and AdV-Dual Ubc9C93S/I/Ulp1. The
levels of the viral antigens detected in each of these cell populations was normalized
against those in the cells transduced with AdV-EGFP and then, compared to each
other. Figure 2.B.3 shows the total cell extracts collected from the non-transduced
samples and provides more conclusive data indicating that there is an increase in
cellular SUMOylation after viral infection, which is independent of an increase in the
levels of any enzyme involved in the SUMO pathway. Furthermore, this figure also
clearly illustrates that the global increase in SUMOylation is not triggered by a
downregulation of the SUMO deconjugating enzyme SENP1. Also, the increase in
global SUMOylation is not unique to SUMO1, but it is also shared by SUMO2/3 as
shown in panel G. The rest of the total cell extracts collected in this same experiment
are shown in figure 2.B.4 conclusively illustrating the effects of the recombinant
adenoviral vectors employed. This array of SUMO1 immunoblots indicate that
transduction by recombinant adenoviruses does not interfere with the increase in global
SUMOylation observed after Influenza A viral infection. More importantly, this increase
is still visible in the samples transduced with the recombinant adenovirus Dual
Ubc9C93S/I/Ulp1.
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Figure 2.B.3- The SUMO conjugation is upregulated during viral infection in A549 cells
without affecting the levels of any component of the SUMO cascade.
A549 cells were mock transduced and infected with Influenza A/WSN1933 at an MOI of 10.
The samples were starved for one hour with cysteine and methionine deficient medium and
then radiolabeled for an additional hour prior to collection. Samples were collected in 2x
sample buffer at 0, 3, 6, 9, 12, 16, 20, and 24 h post-infection. (A-G) Immunoblots of the total
cell extracts collected at the indicated time post-infection directed against the specified
epitopes. (H) Autoradiography of the PVDF membrane when exposed to a phosphor screen
for 2 h and analyzed by using the Personal Molecular Imager (PMI) from BioRad.
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Figure 2.B.4- Transduction of A549 cells with recombinant adenoviruses does not affect
the increase in cellular SUMOylation experienced after Influenza A infection.
A549 cells were transduced with the indicated recombinant adenoviruses to overexpress
EGFP, the biscitronic constructs containing the SUMO conjugating enzyme Ubc9 and the
different SUMO1 mutants, or the bicistronic construct overexpressing the dominant negative
form of Ubc9 with a mutation in the cysteine at position 93 (catalytically inactive mutant)
together with the active site of a SUMO-deconjugating enzyme from yeast Ulp1. 48 h posttransduction, the cells were infected with Influenza A/WSN/1933 at an MOI of 10. The
samples were starved for one hour with cysteine and methionine deficient medium and then
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radiolabeled for an additional hour prior to collection. Samples were collected in 2x sample
buffer at 0, 3, 6, 9, 12, 16, 20, and 24 h post-infection. Panels A-D show the SUMO1
immunoblots of the total cell extracts of the A549 cells transduced with the recombinant
adenoviruses overexpressing either (A) EGFP, (B) His-S-SUMO1Q94P/IRES/Ubc9, (C) HisS-SUMO1ΔGG/IRES/Ubc9, or (D) Ubc9C93S/I/Ulp1.
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Increasing the cellular abundance of SUMO1 leads to an increase in the production of
viral proteins during infection. Finally, the expression profiles for the viral proteins
analyzed show that viral protein production is upregulated when there is an increase in
the levels of SUMO1 present in the cell. Interestingly, the analysis indicates that
SUMO1 does not need to be in the conjugatable form in order to trigger this
upregulation, since approximately the same levels of viral proteins are observed in the
samples transduced with the adenoviruses overexpressing both the conjugatable and
non-conjugatable forms of SUMO1. However, we cannot exclude the possibility that
these changes in the levels of viral antigens observed are due to SUMO interacting with
additional cellular factors involved in regulating translation.
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Figure 2.B.5- Quantification of the levels of the viral proteins produced during infection,
under different conditions of cellular SUMOylation.
The PVDF membranes shown in figure 3.A.2 were exposed to a phosphor screen for 2 h and
analyzed by using the Personal Molecular Imager (PMI) from BioRad. The intensity of the
bands analyzed for each transduced sample was normalized to the intensity of the bands of
their corresponding time point from the non-transduced samples. Panels A-D represent the
relative quantities obtained from the analysis for the viral proteins (A) P proteins, (B) HA, (C)
M1, and (D) NP.
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2.3.C Disregulating cellular SUMOylation does not affect the cellular localization of the
viral protein PB1
The cellular localization of the viral polymerase is not affected by SUMOylation. Given
that one of the main functions of SUMO-conjugation is to affect the cellular localization
of the proteins it modifies. Therefore, we wanted to determine if the effects observed in
the transcriptase activity of the vRdRp after disregulating the cellular SUMOylation
system were due to changes in the cellular localization of the viral polymerase. To
address this question we performed transfection experiments similar to the vRNP
reconstitution assays described above to look at the localization of PB1 under the
different SUMOylation environments by confocal microscopy. In this experiment we
used a c-terminally EGFP-tagged form PB1 (PB1-EGFP) to assess the localization of
the viral polymerase. As shown in figure 2.C.1, the nucleus is the main cellular
compartment to which the viral polymerase localizes. Interestingly, the different
SUMOylation conditions tested in these experiments did not result in any change in the
localization of PB1-EGPF. This is highly suggests that the changes observed in the
transcriptase activity of the RdRp are likely due to something else other than the
sequestration of the viral polymerase to additional cellular compartments.
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Figure 2.C.1- The localization of PB1 is not affected under the different cellular
SUMOylation conditions.
HEK293FT cells were transfected with plasmids encoding an EGFP-tagged form of
PB1, FLAG-tagged forms of PA and PB2, and several additional plasmids to create
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hyper- or hypo- cellular SUMOylation environments already described in figure 2. 24
hours post-transfection immunofluorescent analysis was performed as described by
using the following antibodies: anti-SUMO1MAb, anti-SUMO2/3 MAb, anti-Ubc9 MAb,
and anti-SENP1 MAb. The images were captured using an LSM 700 confocal
microscope (Zeiss. New York, NY) with a 63X objective and three lasers at 405 nm
(DAPI), 488 nm, and 555 nm. ZEN 2009 software (Zeiss. New York, NY), was used for
the acquisition and processing of the confocal images.
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2.3.D Using artificial SUMO-ligases to determine the functionality of SUMO conjugation
on the viral protein PB1
Due to the effects observed on the production of viral antigens by disregulating the
cellular SUMOylation system, our next objective was to use an artificial SUMO-ligase to
specifically increase the SUMOylation of PB1. This will allow us to determine if the
effects seen in the experiment mentioned above were solely due to the SUMOylation of
PB1 and its effects on the transcriptase activity. The development of artificial SUMOligases has proven to be a successful approach in our laboratory for determining the
role of SUMOylation on the viral protein NS1 without altering the activity of the
SUMOylation system by our bicistronic constructs (unpublished data). This was
achieved by creating a fusion protein between the first 83 amino acids of NS1 and the
E2 SUMO-conjugating enzyme Ubc9. Due to the ability of the N-terminus of NS1 to
dimmerize, the SUMO-conjugating enzyme can come into close proximity with the
lysine residues known to be SUMOylated, therefore increasing the SUMOylation of this
targeted protein only. By using the same rationale, we co-transfected the artificial
SUMO-ligase NS1-Ubc9 fusion and PB1 in the either the presence or absence of an
increase of the cellular SUMOylation system by the Dual S1/I/U or Dual S3/I/U
constructs. However, the addition of the artificial SUMO-ligase did not affect the levels o
of SUMOylated PB1 even in the presence of the Dual S1/I/U and Dual S3/I/U
constructs. An additional experiment using the same conditions but substituting the
NS1-Ubc9 fusion for an NP-Ubc9 fusion was performed to trigger an increase in the
SUMOylation of PB1 (data not shown). However, the results also show that the NPUbc9 fusion is not capable of upregulating the SUMOylation of PB1.
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Figure 2.A.2- The SUMOylation of PB1 is not affected by the co-transfection of the
SUMO-artificial ligase NS1-Ubc9.
HEK293FT cells were co-transfected with (+) or without (-) a GFP-tagged form of PB1
(PB1-GFP), a FLAG-tagged form of PA and PB2 (PA-FLAG and PB2-FLAG
respectively), the Dual S1/I/U and Dual S3/I/U, SENP1, NS1-Ubc9 fusion, and an empty
vector to equalize for the amount of DNA transfected per sample. 24 h post-transfection
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the total cell extracts were collected in 2x sample buffer and processed for
immunoblotting. (A-D) Immunoblots of the total cell extracts collected at 24 h posttransfection directed against the specified epitopes.
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2.4 Discussion
Even thought several more experiments are required to demonstrate that PB1 is
SUMOylated during infection, our published manuscript showed for the first time that
PB1 is SUMOylated by both SUMO1 and SUMO2/3 by transfection. Characterizing the
SUMOylation of PB1 during infection has been quite challenging due to the lack of an
antibody that provides good detection and to the fact that only a very small fraction of
the total amount of protein is SUMOylated. This is the reason why several other
approaches such as using an artificial SUMO-ligase were attempted in this study.
On the other hand, after assessing the transcriptase activity under the different
SUMOylation conditions both during transfection by vRNP reconstitution assays and
during infection, we can make the claim that SUMO is playing a key role in the
regulation of viral gene transcription. The fact that the overexpression of SENP1 leads
to a decrease in the transcriptase activity of the vRdRp without affecting its cellular
localization, suggests that SUMOylation might be essential for maintaining a threedimensional structure that allows the formation of stable protein-RNA complexes. These
protein complexes associated to the vRNPs might differ depending on the type of viral
RNA that is being transcribed (e.g. vRNA, vmRNA, and cRNA). To further characterize
the composition of these complexes, immunoprecipitation experiments followed by
mass spectrometry analysis of the pulled down proteins might be needed. Moreover
since this effect is specific of viral mRNA production, these results also further support
the claim that the viral polymerase is a very flexible structure, which has multiple
conformations dependent upon protein-protein and protein-RNA interactions. The
composition of these complexes was addressed by transfection experiments in where
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the trimeric complex of the viral polymerase was expressed under the different
SUMOylation conditions. To prevent the dissociation of these protein complexes we
treated our samples with the cell permeable crosslinker DSG, but unfortunately the
complexes formed where extremely large and were not able to migrate even in 6%
SDS-PAGE gels.
In contrast, it is also interesting that during infection having an excess of SUMO1
in both the conjugatable or non-conjugatable forms increases the production of viral
proteins during infection. This indicates that SUMO1 might be interacting non-covalently
through SUMO-interacting motifs present in the viral polymerase and it is allowing for
the formation of those protein complexes required for viral gene transcription.
Nonetheless, since only the proteins levels were analyzed in this experiment we cannot
determine if this increase was mediated solely by a change in the polymerase
transcriptase activity. However, in the future it might be important to analyze the amino
acid sequence of the PB1, PB2, and PA proteins to determine if they have predicted
SUMO-interacting motifs and determine their function during transcription and
replication. On the other hand, we cannot discard the fact that additional factors
involved in the regulation of translation could be partially responsible for this increase in
protein production.
Lastly, while the experiment shown in figure 2.B.4 reinforces the claim made in
the first chapter that SUMOylation is increased during Influenza A infection, it also
provides evidence for the first time that the increase in global SUMOylation is not
unique to SUMO1, but it is also shared by SUMO2/3. Also, it eliminates the possibility
that this increase is mediated by a downregulation of the SUMO deconjugating enzyme
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SENP1. Moreover, having the same levels of all E1, E2, and SENP1 enzymes
throughout the whole experiment, it is highly indicative that the increase in cellular
SUMOylation is then mediated by E3 SUMO ligases. However, additional experiments
need to be performed in order to answer this question.
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